CA2958316A1 - Abiraterone acetate formulation and methods of use - Google Patents
Abiraterone acetate formulation and methods of use Download PDFInfo
- Publication number
- CA2958316A1 CA2958316A1 CA2958316A CA2958316A CA2958316A1 CA 2958316 A1 CA2958316 A1 CA 2958316A1 CA 2958316 A CA2958316 A CA 2958316A CA 2958316 A CA2958316 A CA 2958316A CA 2958316 A1 CA2958316 A1 CA 2958316A1
- Authority
- CA
- Canada
- Prior art keywords
- abiraterone acetate
- unit dosage
- less
- sodium
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title claims abstract description 348
- 229960004103 abiraterone acetate Drugs 0.000 title claims abstract description 329
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- 238000000034 method Methods 0.000 title claims description 96
- 238000009472 formulation Methods 0.000 title description 25
- 239000002552 dosage form Substances 0.000 claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 179
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 167
- 238000003801 milling Methods 0.000 claims description 99
- 239000002245 particle Substances 0.000 claims description 90
- 238000000227 grinding Methods 0.000 claims description 73
- 238000004090 dissolution Methods 0.000 claims description 47
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 43
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 38
- 238000009837 dry grinding Methods 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 239000003963 antioxidant agent Substances 0.000 claims description 22
- 235000006708 antioxidants Nutrition 0.000 claims description 22
- 230000003078 antioxidant effect Effects 0.000 claims description 17
- 229940051084 zytiga Drugs 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 16
- 239000002270 dispersing agent Substances 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 239000010419 fine particle Substances 0.000 claims description 14
- 239000003352 sequestering agent Substances 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 12
- 239000008363 phosphate buffer Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 239000001530 fumaric acid Substances 0.000 claims description 8
- 229960004618 prednisone Drugs 0.000 claims description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 229960005205 prednisolone Drugs 0.000 claims description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 235000004213 low-fat Nutrition 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- WEMFUFMJQFVTSW-UHFFFAOYSA-N compositin Natural products CC=C(C)C(=O)OC1CC(O)C2(C)COC3C2C1(C)C1CCC2(C)C(CC=C2C1(C)C3OC(=O)C(C)=CC)c1ccoc1 WEMFUFMJQFVTSW-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000007787 solid Substances 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- -1 900 Chemical compound 0.000 description 91
- 239000003826 tablet Substances 0.000 description 87
- 239000011159 matrix material Substances 0.000 description 80
- 239000011734 sodium Substances 0.000 description 55
- 229910052708 sodium Inorganic materials 0.000 description 55
- 229940083542 sodium Drugs 0.000 description 55
- 235000015424 sodium Nutrition 0.000 description 55
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 54
- 229920002675 Polyoxyl Polymers 0.000 description 54
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 49
- 239000000463 material Substances 0.000 description 48
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 44
- 229960001021 lactose monohydrate Drugs 0.000 description 44
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 42
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 42
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 42
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 41
- 229920001223 polyethylene glycol Polymers 0.000 description 38
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 36
- 125000000217 alkyl group Chemical group 0.000 description 34
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 33
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 32
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 30
- 229940016286 microcrystalline cellulose Drugs 0.000 description 30
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 30
- 239000008108 microcrystalline cellulose Substances 0.000 description 30
- 239000000523 sample Substances 0.000 description 30
- 239000000825 pharmaceutical preparation Substances 0.000 description 27
- TVFWYUWNQVRQRG-UHFFFAOYSA-N 2,3,4-tris(2-phenylethenyl)phenol Chemical compound C=1C=CC=CC=1C=CC1=C(C=CC=2C=CC=CC=2)C(O)=CC=C1C=CC1=CC=CC=C1 TVFWYUWNQVRQRG-UHFFFAOYSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 26
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 26
- 229920002517 Poloxamer 338 Polymers 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 229940126534 drug product Drugs 0.000 description 25
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 24
- 239000002202 Polyethylene glycol Substances 0.000 description 24
- 229920001992 poloxamer 407 Polymers 0.000 description 24
- 229940044476 poloxamer 407 Drugs 0.000 description 24
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 23
- 238000009826 distribution Methods 0.000 description 23
- 229920001993 poloxamer 188 Polymers 0.000 description 23
- 229940044519 poloxamer 188 Drugs 0.000 description 23
- 239000000843 powder Substances 0.000 description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 20
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 20
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 19
- 229960001375 lactose Drugs 0.000 description 19
- 239000008101 lactose Substances 0.000 description 19
- 239000012535 impurity Substances 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 239000004094 surface-active agent Substances 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
- 239000011149 active material Substances 0.000 description 16
- 229920002785 Croscarmellose sodium Polymers 0.000 description 15
- 229930006000 Sucrose Natural products 0.000 description 15
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 15
- 229920000847 nonoxynol Polymers 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 15
- 239000005720 sucrose Substances 0.000 description 15
- 239000000454 talc Substances 0.000 description 15
- 229910052623 talc Inorganic materials 0.000 description 15
- 229940033134 talc Drugs 0.000 description 15
- 235000012222 talc Nutrition 0.000 description 15
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 14
- 239000004386 Erythritol Substances 0.000 description 14
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 14
- 229920001732 Lignosulfonate Polymers 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 14
- 150000004996 alkyl benzenes Chemical class 0.000 description 14
- 235000012211 aluminium silicate Nutrition 0.000 description 14
- 229960001681 croscarmellose sodium Drugs 0.000 description 14
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 14
- 229940009714 erythritol Drugs 0.000 description 14
- 235000019414 erythritol Nutrition 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 13
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 description 13
- 239000005995 Aluminium silicate Substances 0.000 description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 229930195725 Mannitol Natural products 0.000 description 13
- 239000008118 PEG 6000 Substances 0.000 description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 13
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 13
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 13
- 229960000853 abiraterone Drugs 0.000 description 13
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- OOCMUZJPDXYRFD-UHFFFAOYSA-L calcium;2-dodecylbenzenesulfonate Chemical compound [Ca+2].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O OOCMUZJPDXYRFD-UHFFFAOYSA-L 0.000 description 13
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 13
- NVVZQXQBYZPMLJ-UHFFFAOYSA-N formaldehyde;naphthalene-1-sulfonic acid Chemical compound O=C.C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 NVVZQXQBYZPMLJ-UHFFFAOYSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 13
- 235000011090 malic acid Nutrition 0.000 description 13
- 239000000594 mannitol Substances 0.000 description 13
- 235000010355 mannitol Nutrition 0.000 description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 13
- FGDMJJQHQDFUCP-UHFFFAOYSA-M sodium;2-propan-2-ylnaphthalene-1-sulfonate Chemical compound [Na+].C1=CC=CC2=C(S([O-])(=O)=O)C(C(C)C)=CC=C21 FGDMJJQHQDFUCP-UHFFFAOYSA-M 0.000 description 13
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 13
- 239000007916 tablet composition Substances 0.000 description 13
- 235000002906 tartaric acid Nutrition 0.000 description 13
- 229940087291 tridecyl alcohol Drugs 0.000 description 13
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 12
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 description 12
- 235000010216 calcium carbonate Nutrition 0.000 description 12
- 239000004359 castor oil Substances 0.000 description 12
- 235000019438 castor oil Nutrition 0.000 description 12
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 12
- 229960000878 docusate sodium Drugs 0.000 description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 12
- 235000010445 lecithin Nutrition 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 12
- 229940067606 lecithin Drugs 0.000 description 12
- 229940099690 malic acid Drugs 0.000 description 12
- 239000001630 malic acid Substances 0.000 description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 12
- 239000011975 tartaric acid Substances 0.000 description 12
- 229960001367 tartaric acid Drugs 0.000 description 12
- NNIYOCKBODDMIU-UHFFFAOYSA-N 1-methylnaphthalene;sodium Chemical compound [Na].C1=CC=C2C(C)=CC=CC2=C1 NNIYOCKBODDMIU-UHFFFAOYSA-N 0.000 description 11
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 11
- 150000008051 alkyl sulfates Chemical class 0.000 description 11
- JIJAYWGYIDJVJI-UHFFFAOYSA-N butyl naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)OCCCC)=CC=CC2=C1 JIJAYWGYIDJVJI-UHFFFAOYSA-N 0.000 description 11
- OMTOSGFDTBPXGW-UHFFFAOYSA-L disodium pentane sulfate Chemical compound [Na+].[Na+].CCCCC.[O-]S([O-])(=O)=O OMTOSGFDTBPXGW-UHFFFAOYSA-L 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 150000003014 phosphoric acid esters Chemical class 0.000 description 11
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 10
- 239000000811 xylitol Substances 0.000 description 10
- 235000010447 xylitol Nutrition 0.000 description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 10
- 229960002675 xylitol Drugs 0.000 description 10
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 235000011087 fumaric acid Nutrition 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 238000001507 sample dispersion Methods 0.000 description 7
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 6
- 229960003964 deoxycholic acid Drugs 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000002952 polymeric resin Substances 0.000 description 6
- 229920003002 synthetic resin Polymers 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 238000000149 argon plasma sintering Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 5
- 238000009490 roller compaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229910001928 zirconium oxide Inorganic materials 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 229920003081 Povidone K 30 Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 229940100242 glycol stearate Drugs 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229940072106 hydroxystearate Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- IJLKAOJMCCICAJ-UHFFFAOYSA-N C=O.CC1=CC=CC2=CC=CC=C12.[Na] Chemical compound C=O.CC1=CC=CC2=CC=CC=C12.[Na] IJLKAOJMCCICAJ-UHFFFAOYSA-N 0.000 description 2
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 229920002696 Polyoxyl 40 castor oil Polymers 0.000 description 2
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920002642 Polysorbate 65 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 2
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UDHMTPILEWBIQI-UHFFFAOYSA-N butyl naphthalene-1-sulfonate;sodium Chemical compound [Na].C1=CC=C2C(S(=O)(=O)OCCCC)=CC=CC2=C1 UDHMTPILEWBIQI-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 235000020937 fasting conditions Nutrition 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229940087068 glyceryl caprylate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940099347 glycocholic acid Drugs 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229940099511 polysorbate 65 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229940046303 sodium cetostearyl sulfate Drugs 0.000 description 2
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 2
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 2
- CLBALUNQCMWJSU-UHFFFAOYSA-L sodium;hexadecyl sulfate;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O CLBALUNQCMWJSU-UHFFFAOYSA-L 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QVHPTAJAHUONLV-DYKIIFRCSA-N (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 QVHPTAJAHUONLV-DYKIIFRCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229910000669 Chrome steel Inorganic materials 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 240000004181 Eucalyptus cladocalyx Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229910000677 High-carbon steel Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 229920003078 Povidone K 12 Polymers 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009291 froth flotation Methods 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- HGPXWXLYXNVULB-UHFFFAOYSA-M lithium stearate Chemical compound [Li+].CCCCCCCCCCCCCCCCCC([O-])=O HGPXWXLYXNVULB-UHFFFAOYSA-M 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical class OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000001415 potassium malate Substances 0.000 description 1
- SVICABYXKQIXBM-UHFFFAOYSA-L potassium malate Chemical compound [K+].[K+].[O-]C(=O)C(O)CC([O-])=O SVICABYXKQIXBM-UHFFFAOYSA-L 0.000 description 1
- 235000011033 potassium malate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 229940100487 povidone k25 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Abstract
The present disclosure relates to pharmaceutical compositions, including solid oral unit dosage forms, comprising abiraterone acetate, wherein the [D50] is greater than 100 nm and less than 1200 nm. The present disclosure further relates touse of the compositions of the disclosure in the treatment of cancer including prostate cancer.
Description
Abiraterone Acetate Formulation and Methods of Use Background Abiraterone ((313)-17-(pyridin-3-y1) androsta-5, 16-dien-3-ol; CAS #: 154229-19-3; Formula:
C24H31N0: Mol. Weight: 349.5 g/mol) is an inhibitor of CYP17 and thus interferes with the synthesis of androgens in the testes, adrenal glands and prostate tumor tissue. Abiraterone acetate (17-(3-Pyridyl) androsta-5, acetate; CAS #154229-18-2), a prodrug of abiraterone, is approved in the United States for treatment of castration-resistant prostate cancer. Abiraterone acetate is considered poorly water soluble.
Zytiga0 Tablets (250 mg; National Drug Code Number 57894-150; NDA 202379) are approved in the United States in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. The prescribing information for Zytiga0 tablets recommends 1,000 mg (4 x 250 mg tablets) administered orally once daily in combination with prednisone (5 mg) administered orally twice daily. The European approval of Zytiga0 is for administration in combination with either prednisone or prednisolone.
Prescribing information for Zytiga0 states that it must be taken on an empty stomach and that no food should be consumed for at least two hours before the dose is taken and for and for at least one hour after the dose is taken. The prescribing information explains that at a dose of 1,000 mg daily in patients with metastatic, castration resistant prostate cancer the steady-state values (mean SD) of Cmax were 226 178 ng/mL and of AUC were 1173 + 690 ng.hr/mL.
A single dose (1000 mg) cross-over study of Zytiga0 in healthy subjects found that systemic exposure of abiraterone is increased when Zytgia0 is administered with food. Specifically, abiraterone Cmax and AUC o, were approximately 7- and 5-fold higher, respectively, when Zytiga0 was administered with a low-fat meal (7% fat, 300 calories) compared to administration in the fasted state. Abiraterone C. and AUC o, were approximately 17- and 10-fold higher, respectively, when Zytiga0 was administered with a high-fat (57% fat, 825 calories) meal compared to administration in the fasted state.
Summary The present disclosure features pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate as well as methods for producing and using such compositions.
Described herein is unit dosage form of abiraterone acetate, wherein a 500mg dose of the unit dosage form is bioequivalent to a 1000mg dose of Zytiga0 in healthy male subjects in the fasted state. Also described is: a unit dosage form of abiraterone acetate, wherein the ratio of the log of the geometric mean of the AUC(0_0,) for a 500mg dose administered to healthy male subjects in the fasted state compared to a 1000mg dose of Zytiga0 administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1; a unit dosage form of abiraterone acetate, wherein the ratio of the log of the geometric mean of the C(max) for a 500mg dose administered to healthy male subjects in the fasted state compared to a 1000mg dose of Zytiga0 administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1.
In some cases: the [D90] of the abiraterone acetate is greater than 300nm and less than one of:
7500nm, 7000nm, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm; the [D50] of the abiraterone acetate greater than 100nm and is less than one of: 3500nm, 3000nm, 2500nm, 1600nm, 1400nm, 1200nm, 1000nm, 800nm, 500nm, 400nm, and 300nm; the [D4,3] of the abiraterone acetate is greater than 300nm and less than one of:
7000nm, 6000nm, 5000nm, 4000nm, 3000nm, 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 1500nm, 1300nm, 1100nm, 900nm, and 800nm; the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.1% sodium lauryl sulfate using USP
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and min; the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 125mg of fine particle abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12% sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the unit dosage form contains125mg of abiraterone acetate.
Also described is a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma Cmax of 50-120 ng/ml. In some cases: a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a median blood plasma tmax of 1 to 2.5 hrs. Described herein is a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood
C24H31N0: Mol. Weight: 349.5 g/mol) is an inhibitor of CYP17 and thus interferes with the synthesis of androgens in the testes, adrenal glands and prostate tumor tissue. Abiraterone acetate (17-(3-Pyridyl) androsta-5, acetate; CAS #154229-18-2), a prodrug of abiraterone, is approved in the United States for treatment of castration-resistant prostate cancer. Abiraterone acetate is considered poorly water soluble.
Zytiga0 Tablets (250 mg; National Drug Code Number 57894-150; NDA 202379) are approved in the United States in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. The prescribing information for Zytiga0 tablets recommends 1,000 mg (4 x 250 mg tablets) administered orally once daily in combination with prednisone (5 mg) administered orally twice daily. The European approval of Zytiga0 is for administration in combination with either prednisone or prednisolone.
Prescribing information for Zytiga0 states that it must be taken on an empty stomach and that no food should be consumed for at least two hours before the dose is taken and for and for at least one hour after the dose is taken. The prescribing information explains that at a dose of 1,000 mg daily in patients with metastatic, castration resistant prostate cancer the steady-state values (mean SD) of Cmax were 226 178 ng/mL and of AUC were 1173 + 690 ng.hr/mL.
A single dose (1000 mg) cross-over study of Zytiga0 in healthy subjects found that systemic exposure of abiraterone is increased when Zytgia0 is administered with food. Specifically, abiraterone Cmax and AUC o, were approximately 7- and 5-fold higher, respectively, when Zytiga0 was administered with a low-fat meal (7% fat, 300 calories) compared to administration in the fasted state. Abiraterone C. and AUC o, were approximately 17- and 10-fold higher, respectively, when Zytiga0 was administered with a high-fat (57% fat, 825 calories) meal compared to administration in the fasted state.
Summary The present disclosure features pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate as well as methods for producing and using such compositions.
Described herein is unit dosage form of abiraterone acetate, wherein a 500mg dose of the unit dosage form is bioequivalent to a 1000mg dose of Zytiga0 in healthy male subjects in the fasted state. Also described is: a unit dosage form of abiraterone acetate, wherein the ratio of the log of the geometric mean of the AUC(0_0,) for a 500mg dose administered to healthy male subjects in the fasted state compared to a 1000mg dose of Zytiga0 administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1; a unit dosage form of abiraterone acetate, wherein the ratio of the log of the geometric mean of the C(max) for a 500mg dose administered to healthy male subjects in the fasted state compared to a 1000mg dose of Zytiga0 administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1.
In some cases: the [D90] of the abiraterone acetate is greater than 300nm and less than one of:
7500nm, 7000nm, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm; the [D50] of the abiraterone acetate greater than 100nm and is less than one of: 3500nm, 3000nm, 2500nm, 1600nm, 1400nm, 1200nm, 1000nm, 800nm, 500nm, 400nm, and 300nm; the [D4,3] of the abiraterone acetate is greater than 300nm and less than one of:
7000nm, 6000nm, 5000nm, 4000nm, 3000nm, 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 1500nm, 1300nm, 1100nm, 900nm, and 800nm; the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.1% sodium lauryl sulfate using USP
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and min; the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 125mg of fine particle abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12% sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the unit dosage form contains125mg of abiraterone acetate.
Also described is a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma Cmax of 50-120 ng/ml. In some cases: a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a median blood plasma tmax of 1 to 2.5 hrs. Described herein is a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood
2 plasma AUC (0-0o) of 240-650 h*ng/ml. In some case the unit dosage form contains 125mg of abiraterone acetate.
Also described is: a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state; and a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma AUC (0-Go) is a value between 240 and 650 h*ng/m1 when a 500mg dose is administered to healthy male subjects in the fasted state.
The unit dosage forms described herein can contain an antioxidant (e.g., one or both of BHA and BHT).
Also described herein is a method for treating castration resistant prostate cancer comprising administering to a patient in need thereof a therapeutically effective dose (e.g., 500mg) of the unit dosage form of abiraterone acetate described herein and a glucocorticoid.
In various embodiments: the glucocorticoid is selected from the group consisting of prednisone, prednisolone and methylprednisolone; the therapeutically effective dose is 500mg/day; the therapeutically effective dose is administered using dosage forms containing:
100mg, 125mg, or 150mg of abiraterone acetate; the 500mg dose is administered using 1, 2, 3, 4, 5, or 6 unit dosage forms.
Described herein is a method for producing a composition comprising abiraterone acetate, the method comprising: dry milling a composition comprising abiraterone acetate, a millable grinding compound, a facilitating agent and one or both of an antioxidant and a sequestering agent in a mill, for a time period sufficient to produce a composition comprising milled abiraterone acetate, wherein the particle size of the abiraterone acetate is reduced by dry milling.
In some cases of the method for production: the [D90] of the abiraterone acetate in the milled composition is greater than 400nm and less than one of: 7500, 7000, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm; the [D50] of the abiraterone acetate in the milled composition is greater than 100nm and is less than 3500nm, 3000nm, 2500nm, less than 1600nm, less than 1400nm, less than 1200nm, less than 1000nm, less than 800nm, less than 500nm, less than 400nm, less than 300nm; the dissolution rate of the
Also described is: a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state; and a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma AUC (0-Go) is a value between 240 and 650 h*ng/m1 when a 500mg dose is administered to healthy male subjects in the fasted state.
The unit dosage forms described herein can contain an antioxidant (e.g., one or both of BHA and BHT).
Also described herein is a method for treating castration resistant prostate cancer comprising administering to a patient in need thereof a therapeutically effective dose (e.g., 500mg) of the unit dosage form of abiraterone acetate described herein and a glucocorticoid.
In various embodiments: the glucocorticoid is selected from the group consisting of prednisone, prednisolone and methylprednisolone; the therapeutically effective dose is 500mg/day; the therapeutically effective dose is administered using dosage forms containing:
100mg, 125mg, or 150mg of abiraterone acetate; the 500mg dose is administered using 1, 2, 3, 4, 5, or 6 unit dosage forms.
Described herein is a method for producing a composition comprising abiraterone acetate, the method comprising: dry milling a composition comprising abiraterone acetate, a millable grinding compound, a facilitating agent and one or both of an antioxidant and a sequestering agent in a mill, for a time period sufficient to produce a composition comprising milled abiraterone acetate, wherein the particle size of the abiraterone acetate is reduced by dry milling.
In some cases of the method for production: the [D90] of the abiraterone acetate in the milled composition is greater than 400nm and less than one of: 7500, 7000, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm; the [D50] of the abiraterone acetate in the milled composition is greater than 100nm and is less than 3500nm, 3000nm, 2500nm, less than 1600nm, less than 1400nm, less than 1200nm, less than 1000nm, less than 800nm, less than 500nm, less than 400nm, less than 300nm; the dissolution rate of the
3 abiraterone acetate in the milled composition is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.1%
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the dissolution rate of the abiraterone acetate in the milled composition is such that when a sample containing 125mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12% sodium lauryl sulfate using USP
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the [D50] of the abiraterone acetate in the milled composition is greater than 200nm and is less than 6500nm, 6000nm, 5500nm, less than 5000nm, less than 4000nm, less than 3000nm, or less than 2000nm; and method the method further comprises:
combining the composition comprising fine particles of abiraterone acetate with one or more pharmaceutically acceptable diluents, disintegrants, lubricants, glidants or dispersants to prepare unit dosage form.
In various embodiments, the particles of abiraterone acetate in the pharmaceutical compositions (or used to prepared the pharmaceutical composition) have a median particle size, determined on a particle volume basis ([D5o] or D[so] or [D50]), equal or less than a size selected from the group consisting of: 5000nm, 4000nm, 3000 nm, 2500nm, 2400 nm, 2300nm, 2200nm, 2200nm, 2100nm, 2000nm, 1900nm, 1800nm, 1700nm, 1600nm, 1500nm, 1400nm, 1300nm, 1200nm, 1100nm, 1000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm and 200nm. In some embodiments, the [D50] is equal to or greater than 25nm or 100nm or even 500nm. In various embodiments the [D50] is between: 5000nm and 100nm, 3500nm and 100nm, 2500nm and 100nm, 1500nm and 100nm, 1200nm and 100nm, 1100nm and 100nm, 1000nm and 100nm, 800nm and 100nm, 700nm and 100nm, 600nm and 100nm, 500nm and 100nm. The D[4,3]
(volume mean diameter) in various embodiments is: less than 7000nm, less than 5000nm, less than 3500nm, less than 3000 nm, less than 2000 nm, less than 1000 or less than 300nm. In various cases, such as those described previously, the D[4,3] is greater than 100nm or greater than 200nm. In some cases the D[4,3] (volume mean diameter) is between: 7000nm and 1000nm, 6000nm and 200nm, 5000nm and 1000nm, 4000nm and 1000nm, 3000nm and 1000nm, 2000nm and 1000nm, 1800nm and 1000nm, 1600nm and 1000nm, 1500nm and 1000nm, 1500nm and 500nm, 4000nm and 2000nm, 4000nm and 100nm, 25000nm and 500nm, 700nm and 100nm, 600nm and 100nm, 500nm and 100nm 1000nm and 200nm, 900nm and 200nm, 800nm and 200nm, 700nm and 200nm. The [D90] ([D90] or D[9o]) in various embodiments is: less than 8000nm, less than 7500nm, less than 7000nm, less than 6000nm, less than 4000 nm, less than 2000nm, less than 1000nm, less than 500nm. In some cases, the D90 is
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the dissolution rate of the abiraterone acetate in the milled composition is such that when a sample containing 125mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12% sodium lauryl sulfate using USP
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min; the [D50] of the abiraterone acetate in the milled composition is greater than 200nm and is less than 6500nm, 6000nm, 5500nm, less than 5000nm, less than 4000nm, less than 3000nm, or less than 2000nm; and method the method further comprises:
combining the composition comprising fine particles of abiraterone acetate with one or more pharmaceutically acceptable diluents, disintegrants, lubricants, glidants or dispersants to prepare unit dosage form.
In various embodiments, the particles of abiraterone acetate in the pharmaceutical compositions (or used to prepared the pharmaceutical composition) have a median particle size, determined on a particle volume basis ([D5o] or D[so] or [D50]), equal or less than a size selected from the group consisting of: 5000nm, 4000nm, 3000 nm, 2500nm, 2400 nm, 2300nm, 2200nm, 2200nm, 2100nm, 2000nm, 1900nm, 1800nm, 1700nm, 1600nm, 1500nm, 1400nm, 1300nm, 1200nm, 1100nm, 1000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm and 200nm. In some embodiments, the [D50] is equal to or greater than 25nm or 100nm or even 500nm. In various embodiments the [D50] is between: 5000nm and 100nm, 3500nm and 100nm, 2500nm and 100nm, 1500nm and 100nm, 1200nm and 100nm, 1100nm and 100nm, 1000nm and 100nm, 800nm and 100nm, 700nm and 100nm, 600nm and 100nm, 500nm and 100nm. The D[4,3]
(volume mean diameter) in various embodiments is: less than 7000nm, less than 5000nm, less than 3500nm, less than 3000 nm, less than 2000 nm, less than 1000 or less than 300nm. In various cases, such as those described previously, the D[4,3] is greater than 100nm or greater than 200nm. In some cases the D[4,3] (volume mean diameter) is between: 7000nm and 1000nm, 6000nm and 200nm, 5000nm and 1000nm, 4000nm and 1000nm, 3000nm and 1000nm, 2000nm and 1000nm, 1800nm and 1000nm, 1600nm and 1000nm, 1500nm and 1000nm, 1500nm and 500nm, 4000nm and 2000nm, 4000nm and 100nm, 25000nm and 500nm, 700nm and 100nm, 600nm and 100nm, 500nm and 100nm 1000nm and 200nm, 900nm and 200nm, 800nm and 200nm, 700nm and 200nm. The [D90] ([D90] or D[9o]) in various embodiments is: less than 8000nm, less than 7500nm, less than 7000nm, less than 6000nm, less than 4000 nm, less than 2000nm, less than 1000nm, less than 500nm. In some cases, the D90 is
4 between: 5500nm and 300nm, 5000nm and 500nm, 4500nm and 500nm, 4000nm and 200nm, 4500nm and 750nm, and 3500nm and 500nm. In various embodiments described herein the [D90] of the abiraterone acetate is less than 5000nm or less than 4000nm. In some embodiments the [D90] is: 6000nm-500nm, 5500nm-500nm, or 5000nm-500nm, and 4000-400nm.
In another embodiment, the crystallinity profile of the abiraterone acetate is selected from the group consisting of: at least 20% of the abiraterone acetate is crystalline, at least 30% of the abiraterone acetate is crystalline, at least 40% of the abiraterone acetate is crystalline, at least 50% of the abiraterone acetate is crystalline, at least 60% of the abiraterone acetate is crystalline, at least 70% of the abiraterone acetate is crystalline, at least 75% of the abiraterone acetate is crystalline, at least 85% of the abiraterone acetate is crystalline, at least 90% of the abiraterone acetate is crystalline, at least 95% of the abiraterone acetate is crystalline and at least 98% of the abiraterone acetate is crystalline. In some embodiments, the crystallinity profile of the abiraterone acetate is substantially equal to the crystallinity profile of the abiraterone acetate before the material was subjected to the method as described herein.
In another embodiment, the amorphous content of the abiraterone acetate is selected from the group consisting of: less than 80% of the abiraterone acetate is amorphous, less than 70% of the abiraterone acetate is amorphous, less than 60% of the abiraterone acetate is amorphous, less than 50% of the abiraterone acetate is amorphous, less than 40% of the abiraterone acetate is amorphous, less than 30% of the abiraterone acetate is amorphous, less than 25% of the abiraterone acetate is amorphous, less than 15% of the abiraterone acetate is amorphous, less than 10% of the abiraterone acetate is amorphous, less than 5% of the abiraterone acetate is amorphous and less than 2% of the abiraterone acetate is amorphous. In some embodiments, the abiraterone acetate has no significant increase in amorphous content after subjecting the material to the dry milling method described herein.
In some embodiments, the particles of abiraterone acetate are prepared by dry milling abiraterone acetate with a millable grinding compound and a facilitating agent in the presence of milling bodies. Additional components can be present during the milling and together the various components present during milling (with the exception of abiraterone acetate and the milling bodies) are referred to as a grinding matrix. In some cases, the milling produces particles of abiraterone acetate that are significantly reduced in size dispersed in grinding matrix.
Because all of the components in the grinding matrix are pharmaceutically acceptable, pharmaceutical compositions can be prepared using the mixture of abiraterone acetate and grinding matrix produced by the milling. In some cases some or all of the components of the grinding matrix are reduced in size during milling. In some cases additional pharmaceutically acceptable components can be added to the mixture of abiraterone acetate and grinding matrix subsequent to milling. In some embodiments, the dry milling takes place in the presence of milling bodies; in other cases the particles are produced by milling in the absence of milling bodies, for example, by milling in jet mill or another type of mill, for example a mill that can reduce the particle size and/or increase the solublity of abiraterone acetate when the abiraterone acetate is milling in presence of millable grinding compound, which itself may or may not be reduced in particle size.
In some cases abiraterone acetate is milled with one or more millable grinding compounds selected from: lactose (e.g., lactose monohydrate or lactose anhydrous) and mannitol and one or more facilitating agents selected from sodium lauryl sulfate and povidone. In some cases, the milling, in addition to reducing the particle size of the abiraterone acetate, reduces the particle size of one or more components of the grinding matrix. Thus, in some cases, the milling reduces the particles of one or more of the materials (e.g., lactose) used as the millable grinding compound. In some cases, abiraterone acetate is milled with lactose (e.g., lactose monohydrate) and sodium lauryl sulfate. In some cases during dry milling the abiraterone acetate can be present at 20-60% (w/w) the lactose at up to 80% (w/w) the mannitol at up to 80% (w/w) and the povidone and sodium lauryl sulfate each (or both) at 1-10% (w/w).
In some embodiments, the abiraterone acetate is dry milled in the presence of one or more antioxidants and/or one or more sequestering agents (i.e., an agent that can sequester ions, e.g, metal ions) in addition to at least one millable grinding compound and at least one facilitating agent. Thus, one or more of: butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) or mixtures thereof can be present during the dry milling. In some cases, both at least one antioxidant and at least one sequestering agent are present during milling. During milling, the ascorbic acid, fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) can be present at 8% or less on a w/w basis (e.g., 7%-0.1%, 1%-0.1%, or 0.2% each or in combination) and the BHT and BHA can be present at 0.5% or less (e.g., 0.5% - 0.01%, 0.2% ¨ 0.08%, 0.15%-0.05%, or 0.1%
each or in combination). One or more additional antioxidants and/or one or more additional sequestering agents can be added to the milled material after milling is completed.
The pharmaceutical composition can be a unit dosage form such as a capsule or tablet containing 50 - 500 mg of abiraterone acetate (e.g, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475 or 500 mg), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein.
Also described herein is a method for treating a patient comprising administering a daily dose of 1000mg to 50mg of abiraterone acetate (e.g, 900, 850, 800, 750, 700, 650, 600, 550, 525, 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250, 225, 200, 150, 100, 90, 80, 70, 60, or 50 mg) in the form of a pharmaceutical composition described herein (e.g, by administering one or more units of a unit dosage form described herein comprising abiraterone acetate), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein. The patient can also be treated with a glucocorticoid such as prednisone, prednisolone, or dexamethasone. Alternatively, the patient can also be treated with methylprednisolone, for example at 5-15 mg/day (e.g., 5, 6, 7, 8, 9, 10 mg/day, for example two 4mg doses/day). In some cases a patient, e.g., a patient not suffering from hepatic impairment, is treated at 500mg/daily by administering four 125mg unit dosage forms of abiraterone acetate as described herein.
In some cases, for the dosage forms described herein, the AUC o-. for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 4-fold or less (3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the AUC (or AUC
o-t) for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 8-fold or less (7-fold or less, 5-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the Cmax for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 15-fold or less (13-fold or less or, 12-fold or less, 11-fold or less, 10-fold or less, 9-fold or less, 8-fold or less, 7-fold or less, 6-fold or less, 5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the Cmax for a single dose of a unit dosage form described herein (or an approved dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 6-fold or less (5-fold or less or 4-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
The dissolution rate of a tablet containing 100mg or 125 mg of abiraterone acetate when tested in 900 ml of pH 4.5 phosphate buffer with 0.1% -0.12% sodium lauryl sulfate (respectively) using USP Apparatus II at 75 rpm, is such that at least 90% or at least 95% of the abiraterone acetate dissolves in 20 min or less (e.g, 19 mm or less, 18 min or less, 17 mm or less, 16 min or less, 15 min or less, 14 min or less, 13 min or less, 11 min or less, 9 mm or less). For example, 90% can dissolve in 9-19 minutes. In cases where the tablet contains more than 125mg or less than 100mg of abiraterone acetate, the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate. In some cases, at least 80% or at least 85% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 12 min or less, 11 min or less, 10 mm or less, 9 min or less, 8 min or less, or 7 min or less). For example, 85% can dissolve in 7-14 minutes.
In some cases, at least 80% or at least 85% of the abiraterone acetate in a 125mg unit dosage form dissolves in 15 mm or less (e.g, 14 mm or less, 13 mm or less, 12 min or less, 11 mm or less, 10 min or less, 9 min or less, 8 mm or less, or 7 min or less) after storage at 4 weeks or more (e.g., 8 weeks or 12 weeks) at 25 C at 60% RH. In some cases, at least 95% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 11 min or less, 9 min or less) after storage at 3 weeks or more (e.g., 6 weeks or 9 weeks) at 40 C at 75% RH.
For example, 95% can dissolve in 8-14 min. Here too, in cases where the tablet contains more than 125mg or less than 100mg of abiraterone acetate, the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate.
In certain embodiments, the coefficient of variation observed for a pharmaceutical composition described herein in one or more of Cmax, AUC(0-t), and AUC(0-Go) will be less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, or less than 20% when administered to healthy patients in the fasted state. In some embodiments, a pharmaceutical composition described herein (125mg unit dosage form or a 500mg dose of a unit dosage form, e.g., 4 x 125mg) shows less variability in one or more of Cmax, AUC(0-t), and AUC(0-Do) relative to, e.g., a 250mg dosage form of Zytiga0 (or a 1000 dose of a a 250mg dosage form of Zytiga0) in comparative pharmacokinetic testing.
In some cases, the hardness of abiraterone tablets is between 100N and 190N
(e.g., 110N to 180N).
The drug product intermediate can be prepared by dry milling the following materials: (A) abiraterone acetate at 5-60 weight percent, lactose (e.g., lactose monohydrate) at 30-95 weight percent, sodium lauryl sulfate at 0.1-15 weight percent; BHA at 0.001-1 weight percent, and BHT at 0.001-1 weight percent; (B) abiraterone acetate at 10-50 weight percent, lactose (e.g., lactose monohydrate) at 40-80 weight percent, sodium lauryl sulfate at 0.5-10 weight percent;
BHA at 0.01-0.8 weight percent, and BHT at 0.01-0.8 weight percent; (C) abiraterone acetate at 20-40 weight percent, lactose (e.g., lactose monohydrate) at 50-70 weight percent, sodium lauryl sulfate at 2-8 weight percent; BHA at 0.05-0.5 weight percent, and BHT at 0.05-0.5 weight percent; (D) abiraterone acetate at 25-35 weight percent, lactose (e.g., lactose monohydrate) at -60-70 weight percent, sodium lauryl sulfate at 4-8 weight percent; BHA at 0.05-0.15 weight percent, and BHT at 0.05-0.15 weight percent; and (E) abiraterone acetate at 30 weight percent, lactose (e.g., lactose monohydrate) at 63.8 weight percent, sodium lauryl sulfate at 6 weight percent; BHA at 0.1 weight percent, and BHT at 0.1 weight percent.
Drug product intermediate described above can be processed into tablets having the following materials: (A) abiraterone acetate at 5-50 weight percent, lactose (e.g., lactose monohydrate) at
In another embodiment, the crystallinity profile of the abiraterone acetate is selected from the group consisting of: at least 20% of the abiraterone acetate is crystalline, at least 30% of the abiraterone acetate is crystalline, at least 40% of the abiraterone acetate is crystalline, at least 50% of the abiraterone acetate is crystalline, at least 60% of the abiraterone acetate is crystalline, at least 70% of the abiraterone acetate is crystalline, at least 75% of the abiraterone acetate is crystalline, at least 85% of the abiraterone acetate is crystalline, at least 90% of the abiraterone acetate is crystalline, at least 95% of the abiraterone acetate is crystalline and at least 98% of the abiraterone acetate is crystalline. In some embodiments, the crystallinity profile of the abiraterone acetate is substantially equal to the crystallinity profile of the abiraterone acetate before the material was subjected to the method as described herein.
In another embodiment, the amorphous content of the abiraterone acetate is selected from the group consisting of: less than 80% of the abiraterone acetate is amorphous, less than 70% of the abiraterone acetate is amorphous, less than 60% of the abiraterone acetate is amorphous, less than 50% of the abiraterone acetate is amorphous, less than 40% of the abiraterone acetate is amorphous, less than 30% of the abiraterone acetate is amorphous, less than 25% of the abiraterone acetate is amorphous, less than 15% of the abiraterone acetate is amorphous, less than 10% of the abiraterone acetate is amorphous, less than 5% of the abiraterone acetate is amorphous and less than 2% of the abiraterone acetate is amorphous. In some embodiments, the abiraterone acetate has no significant increase in amorphous content after subjecting the material to the dry milling method described herein.
In some embodiments, the particles of abiraterone acetate are prepared by dry milling abiraterone acetate with a millable grinding compound and a facilitating agent in the presence of milling bodies. Additional components can be present during the milling and together the various components present during milling (with the exception of abiraterone acetate and the milling bodies) are referred to as a grinding matrix. In some cases, the milling produces particles of abiraterone acetate that are significantly reduced in size dispersed in grinding matrix.
Because all of the components in the grinding matrix are pharmaceutically acceptable, pharmaceutical compositions can be prepared using the mixture of abiraterone acetate and grinding matrix produced by the milling. In some cases some or all of the components of the grinding matrix are reduced in size during milling. In some cases additional pharmaceutically acceptable components can be added to the mixture of abiraterone acetate and grinding matrix subsequent to milling. In some embodiments, the dry milling takes place in the presence of milling bodies; in other cases the particles are produced by milling in the absence of milling bodies, for example, by milling in jet mill or another type of mill, for example a mill that can reduce the particle size and/or increase the solublity of abiraterone acetate when the abiraterone acetate is milling in presence of millable grinding compound, which itself may or may not be reduced in particle size.
In some cases abiraterone acetate is milled with one or more millable grinding compounds selected from: lactose (e.g., lactose monohydrate or lactose anhydrous) and mannitol and one or more facilitating agents selected from sodium lauryl sulfate and povidone. In some cases, the milling, in addition to reducing the particle size of the abiraterone acetate, reduces the particle size of one or more components of the grinding matrix. Thus, in some cases, the milling reduces the particles of one or more of the materials (e.g., lactose) used as the millable grinding compound. In some cases, abiraterone acetate is milled with lactose (e.g., lactose monohydrate) and sodium lauryl sulfate. In some cases during dry milling the abiraterone acetate can be present at 20-60% (w/w) the lactose at up to 80% (w/w) the mannitol at up to 80% (w/w) and the povidone and sodium lauryl sulfate each (or both) at 1-10% (w/w).
In some embodiments, the abiraterone acetate is dry milled in the presence of one or more antioxidants and/or one or more sequestering agents (i.e., an agent that can sequester ions, e.g, metal ions) in addition to at least one millable grinding compound and at least one facilitating agent. Thus, one or more of: butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) or mixtures thereof can be present during the dry milling. In some cases, both at least one antioxidant and at least one sequestering agent are present during milling. During milling, the ascorbic acid, fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) can be present at 8% or less on a w/w basis (e.g., 7%-0.1%, 1%-0.1%, or 0.2% each or in combination) and the BHT and BHA can be present at 0.5% or less (e.g., 0.5% - 0.01%, 0.2% ¨ 0.08%, 0.15%-0.05%, or 0.1%
each or in combination). One or more additional antioxidants and/or one or more additional sequestering agents can be added to the milled material after milling is completed.
The pharmaceutical composition can be a unit dosage form such as a capsule or tablet containing 50 - 500 mg of abiraterone acetate (e.g, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475 or 500 mg), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein.
Also described herein is a method for treating a patient comprising administering a daily dose of 1000mg to 50mg of abiraterone acetate (e.g, 900, 850, 800, 750, 700, 650, 600, 550, 525, 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250, 225, 200, 150, 100, 90, 80, 70, 60, or 50 mg) in the form of a pharmaceutical composition described herein (e.g, by administering one or more units of a unit dosage form described herein comprising abiraterone acetate), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein. The patient can also be treated with a glucocorticoid such as prednisone, prednisolone, or dexamethasone. Alternatively, the patient can also be treated with methylprednisolone, for example at 5-15 mg/day (e.g., 5, 6, 7, 8, 9, 10 mg/day, for example two 4mg doses/day). In some cases a patient, e.g., a patient not suffering from hepatic impairment, is treated at 500mg/daily by administering four 125mg unit dosage forms of abiraterone acetate as described herein.
In some cases, for the dosage forms described herein, the AUC o-. for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 4-fold or less (3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the AUC (or AUC
o-t) for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 8-fold or less (7-fold or less, 5-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the Cmax for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 15-fold or less (13-fold or less or, 12-fold or less, 11-fold or less, 10-fold or less, 9-fold or less, 8-fold or less, 7-fold or less, 6-fold or less, 5-fold or less) higher than when administered in the fasted state.
In some cases, for the dosage forms described herein, the Cmax for a single dose of a unit dosage form described herein (or an approved dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 6-fold or less (5-fold or less or 4-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
The dissolution rate of a tablet containing 100mg or 125 mg of abiraterone acetate when tested in 900 ml of pH 4.5 phosphate buffer with 0.1% -0.12% sodium lauryl sulfate (respectively) using USP Apparatus II at 75 rpm, is such that at least 90% or at least 95% of the abiraterone acetate dissolves in 20 min or less (e.g, 19 mm or less, 18 min or less, 17 mm or less, 16 min or less, 15 min or less, 14 min or less, 13 min or less, 11 min or less, 9 mm or less). For example, 90% can dissolve in 9-19 minutes. In cases where the tablet contains more than 125mg or less than 100mg of abiraterone acetate, the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate. In some cases, at least 80% or at least 85% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 12 min or less, 11 min or less, 10 mm or less, 9 min or less, 8 min or less, or 7 min or less). For example, 85% can dissolve in 7-14 minutes.
In some cases, at least 80% or at least 85% of the abiraterone acetate in a 125mg unit dosage form dissolves in 15 mm or less (e.g, 14 mm or less, 13 mm or less, 12 min or less, 11 mm or less, 10 min or less, 9 min or less, 8 mm or less, or 7 min or less) after storage at 4 weeks or more (e.g., 8 weeks or 12 weeks) at 25 C at 60% RH. In some cases, at least 95% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 11 min or less, 9 min or less) after storage at 3 weeks or more (e.g., 6 weeks or 9 weeks) at 40 C at 75% RH.
For example, 95% can dissolve in 8-14 min. Here too, in cases where the tablet contains more than 125mg or less than 100mg of abiraterone acetate, the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate.
In certain embodiments, the coefficient of variation observed for a pharmaceutical composition described herein in one or more of Cmax, AUC(0-t), and AUC(0-Go) will be less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, or less than 20% when administered to healthy patients in the fasted state. In some embodiments, a pharmaceutical composition described herein (125mg unit dosage form or a 500mg dose of a unit dosage form, e.g., 4 x 125mg) shows less variability in one or more of Cmax, AUC(0-t), and AUC(0-Do) relative to, e.g., a 250mg dosage form of Zytiga0 (or a 1000 dose of a a 250mg dosage form of Zytiga0) in comparative pharmacokinetic testing.
In some cases, the hardness of abiraterone tablets is between 100N and 190N
(e.g., 110N to 180N).
The drug product intermediate can be prepared by dry milling the following materials: (A) abiraterone acetate at 5-60 weight percent, lactose (e.g., lactose monohydrate) at 30-95 weight percent, sodium lauryl sulfate at 0.1-15 weight percent; BHA at 0.001-1 weight percent, and BHT at 0.001-1 weight percent; (B) abiraterone acetate at 10-50 weight percent, lactose (e.g., lactose monohydrate) at 40-80 weight percent, sodium lauryl sulfate at 0.5-10 weight percent;
BHA at 0.01-0.8 weight percent, and BHT at 0.01-0.8 weight percent; (C) abiraterone acetate at 20-40 weight percent, lactose (e.g., lactose monohydrate) at 50-70 weight percent, sodium lauryl sulfate at 2-8 weight percent; BHA at 0.05-0.5 weight percent, and BHT at 0.05-0.5 weight percent; (D) abiraterone acetate at 25-35 weight percent, lactose (e.g., lactose monohydrate) at -60-70 weight percent, sodium lauryl sulfate at 4-8 weight percent; BHA at 0.05-0.15 weight percent, and BHT at 0.05-0.15 weight percent; and (E) abiraterone acetate at 30 weight percent, lactose (e.g., lactose monohydrate) at 63.8 weight percent, sodium lauryl sulfate at 6 weight percent; BHA at 0.1 weight percent, and BHT at 0.1 weight percent.
Drug product intermediate described above can be processed into tablets having the following materials: (A) abiraterone acetate at 5-50 weight percent, lactose (e.g., lactose monohydrate) at
5-80 weight percent, sodium lauryl sulfate at 0.1-10 weight percent, BHA at 0.001-1 weight percent, BHT at 0.001-1 weight percent, microcrystalline cellulose at 5-80 weight percent croscarmellose sodium at 0.5-20 weight percent, and sodium stearyl fumarate at 0.01-10 weight percent; (B) abiraterone acetate at 8-40 weight percent, lactose (e.g., lactose monohydrate) at 10-60 weight percent, sodium lauryl sulfate at 0.5-8 weight percent, BHA at 0.01-0.05 weight percent, BHT at 0.01-0.5 weight percent, microcrystalline cellulose at 10-70 weight percent, croscarmellose sodium at 1-15 weight percent, and sodium stearyl fumarate at 0.05-5 weight percent; (C) abiraterone acetate at 10-30 weight percent, lactose (e.g., lactose monohydrate) at 20-40 weight percent, sodium lauryl sulfate at 1-5 weight percent; BHA at 0.01-0.2 weight percent, BHT at 0.01-0.2 weight percent, microcrystalline cellulose at 20-60 weight percent, croscarmellose sodium at 2-10 weight percent, and sodium stearyl fumarate at 0.1-2 weight percent; (D) abiraterone acetate at 12-17 weight percent, lactose (e.g., lactose monohydrate) at 25-35 weight percent, sodium lauryl sulfate at 2-5 weight percent; BHA at 0.01-0.2 weight percent, BHT at 0.01-0.2 weight percent, microcrystalline cellulose at 35-50 weight percent, croscarmellose sodium at 5-9 weight percent, and sodium stearyl fumarate at 0.2-0.8 weight percent; and (E) abiraterone acetate at 14.29 weight percent, lactose (e.g., lactose monohydrate) at 30.38 weight percent, sodium lauryl sulfate at 3.21 weight percent; BHA at 0.05 weight percent, BHT at 0.05 weight percent, microcrystalline cellulose at 44-53 weight percent, croscarmellose sodium at 7 weight percent, and sodium stearyl fumarate at 0.5 weight percent.
In some embodiments, the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: attritor mills (horizontal or vertical), nutating mills, tower mills, pearl mills, planetary mills, vibratory mills, eccentric vibratory mills, gravity-dependent-type ball mills, rod mills, roller mills and crusher mills. In some embodiments, the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: jet mills, spiral jet mills, micronisers or pulverizers. Preferably, the method is configured to produce the abiraterone acetate in a swing batch or continuous fashion.
In some embodiments, where a mill uses milling bodies, the milling bodies within the milling apparatus are mechanically agitated by 1, 2 or 3 rotating shafts. The milling bodies can be formed of a material selected from the group consisting of: ceramics, glasses, steels, polymers, ferromagnetics and metals and other suitable materials. In some embodiments, the milling bodies are steel balls having a diameter selected from the group consisting of:
between 1 and 20 mm, between 2 and 15 mm and between 3 and 10 mm. In various embodiments of the dry milling method, the milling bodies are zirconium oxide balls having a diameter selected from the group consisting of: between 1 and 20 mm, between 2 and 15 mm and between 3 and 10 mm.
In another embodiment, the milling time period is a range selected from the group consisting of:
between 10 minutes and 6 hours, between 10 minutes and 2 hours, between 10 minutes and 90 minutes, between 10 minutes and 1 hour, between 10 minutes and 45 minutes, between 10 minutes and 30 minutes, between 5 minutes and 30 minutes, between 5 minutes and 20 minutes, between 2 minutes and 10 minutes, between 2 minutes and 5 minutes, between 1 minutes and 2 minutes.
Additional Milling Matrixes and Facilitating Agents In embodiments, the grinding matrix is a single material or is a mixture of two or more materials in any proportion. In some embodiments, the single material or a mixture of two or more materials is selected from the group consisting of: mannitol, sorbitol, isomalt, xylitol, maltitol, lactitol, erythritol, arabitol, ribitol, glucose, fructose, mannose, galactose, anhydrous lactose, lactose monohydrate, sucrose, maltose, trehalose, and maltodextrins. In some embodiments the single material or mixture of two or more materials is selected from the group consisting of:
dextrin, inulin, dextrates, polydextrose, starch, wheat flour, corn flour, rice flour, rice starch, tapioca flour, tapioca starch, potato flour, potato starch, other flours and starches, milk powder, skim milk powders, other milk solids and derivatives, soy flour, soy meal or other soy products, cellulose, microcrystalline cellulose, microcrystalline cellulose based co-blended materials, pregelatinized (or partially gelatinized) starch, hypromellose, carboxymethyl cellulose, hydroxypropyl cellulose, citric acid, tartaric acid, malic acid, maleic acid, fumaric acid, ascorbic acid, succinic acid, sodium citrate, sodium tartrate, sodium malate, sodium ascorbate, potassium citrate, potassium tartrate, potassium malate, sodium acetate, potassium ascorbate, sodium carbonate, potassium carbonate, magnesium carbonate, sodium bicarbonate, potassium bicarbonate, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, sodium sulfate, sodium chloride, sodium metabisulphite, sodium thiosulfate, ammonium chloride, glauber's salt, ammonium carbonate, sodium bisulfate, magnesium sulfate, potash alum, potassium chloride, sodium hydrogen sulfate, sodium hydroxide, crystalline hydroxides, hydrogen carbonates, ammonium chloride, methylamine hydrochloride, ammonium bromide, silica, thermal silica, alumina, titanium dioxide, talc, chalk, mica, kaolin, bentonite, hectorite, magnesium trisilicate, clay based materials or aluminium silicates, sodium lauryl sulfate, sodium stearyl sulfate, sodium cetyl sulfate, sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate, glycerol distearate glyceryl palmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate, benzalkonium chloride, cetrimonium bromide, cetrimonium chloride, cetrimide, cetylpyridinium chloride, cetylpyridinium bromide, benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil, polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil, polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15 hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trioleate, sucrose palmitate, sucrose stearate, sucrose distearate, sucrose laurate, glycocholic acid, sodium glycholate, cholic acid, sodium cholate, sodium deoxycholate, deoxycholic acid, sodium taurocholate, taurocholic acid, sodium taurodeoxycholate, taurodeoxycholic acid, soy lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalene sulfonate condensate/Lignosulfonate blend, calcium dodecylbenzene sulfonate, sodium dodecylbenzene sulfonate, diisopropyl naphthaenesulphonate, erythritol distearate, naphthalene sulfonate formaldehyde condensate, nonylphenol ethoxylate (poe-30), tristyrylphenol ethoxylate, polyoxyethylene (15) tallowalkylamines, sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonate condensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalene sulfonate, sodium methyl naphthalene formaldehyde sulfonate, sodium n-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18), triethanolamine isodecanol phosphate ester, triethanolamine tristyrylphosphate ester, tristyrylphenol ethoxylate sulfate, bis(2-hydroxyethyl)tallowalkylamines.
In some embodiments, the concentration of the single (or first) component of the grinding matrix is selected from the group consisting of: 5 - 99 % w/w, 10 - 95 % w/w, 15 - 85 % w/w, of 20 ¨
80% w/w, 25 - 75 % w/w, 30 - 60% w/w, 40 -50% w/w. In some embodiments, the concentration of the second or subsequent component of the grinding matrix is selected from the group consisting of: 5 - 50 % w/w, 5 - 40 % w/w, 5 - 30 % w/w, of 5 ¨ 20% w/w, 10 - 40 %
w/w, 10 -30% w/w, 10 -20% w/w, 20 - 40% w/w, or 20 - 30% w/w or if the second or subsequent material is a surfactant or water soluble polymer the concentration is selected from 0.1 -10 % w/w, 0.1-5 % w/w, 0.1 -2.5 % w/w, of 0.1 ¨2% w/w, 0.1 -1 %, 0.5 -5%w/w, 0.5 -3%
w/w, 0.5 -2% w/w, 0.5 ¨ 1.5%, 0.5 -1 % w/w, of 0.75 ¨ 1.25 % w/w, 0.75 -1% and 1% w/w.
In some embodiments, abiraterone acetate is milled in the presence of:
(a) Lactose monohydrate or lactose monohydrate combined with at least one material selected from the group consisting of: xylitol; lactose anhydrous;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(b) Lactose anhydrous or lactose anhydrous combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(c) Mannitol or mannitol combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; lactose anhydrous;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(d) Sucrose or sucrose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(e) Glucose or glucose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(f) Sodium chloride or sodium chloride combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous;
mannitol;
microcrystalline cellulose; sucrose; glucose; talc; kaolin; calcium carbonate;
malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde Sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(g) Xylitol or xylitol combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(h) Tartaric acid or tartaric acid combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin;
calcium carbonate; malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and Polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; Phosphate Esters, tristyrylphenol Ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(i) Microcrystalline cellulose or microcrystalline cellulose combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol;
lactose anhydrous; mannitol; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid;
sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether;
polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium;
polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG
3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and Polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate;
erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines;
sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate;
sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(j) Kaolin combined with at least one material selected from the group consisting of:
lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystalline cellulose;
sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; Polyoxyl 100 stearyl ether; Polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
Hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
briethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(k) Talc combined with at least one material selected from the group consisting of:
lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystalline cellulose;
sucrose; glucose; sodium chloride; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
In some embodiments, the abiraterone acetate is dry milled with one or more additional materials is selected from the group consisting of: a material considered to be 'Generally Regarded as Safe' (GRAS) for pharmaceutical products.
In some embodiments, the dry milling of abiraterone acetate takes place in the presence of a facilitating agent or combination of facilitating agents. In some embodiments, the facilitating agent is selected from the group consisting of: a glidant, a surfactant, a polymer, and/or a lubricant. In some embodiments, the facilitating agent is selected from the group consisting of:
colloidal silicon dioxide, sodium stearate and talc. In some embodiments, the facilitating agent is selected from the group consisting of: benzethonium chloride, docusate sodium, polyethylene alkyl ethers, sodium lauryl sulfate, tricaprylin, alpha tocopherol, glyceryl monooleate, myristyl alcohol, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene stearates, polyoxyethylene castor oil derivatives, polyoxyl 15 hydroxystearate, polyoxylglycerides, polysorbates, propylene glycol dilaurate, sorbitan esters, sucrose palmitate, vitamin E polyethylene glycol succinate, polyethylene glycols (PEG), poloxamers, poloxamines, sarcosine based surfactants, polysorbates, aliphatic alcohols, alkyl and aryl sulfates, alkyl and aryl polyether sulfonates and other sulfate surfactants, trimethyl ammonium based surfactants, lecithin and other phospholipids, bile salts, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters sucrose fatty acid esters, alkyl glucopyranosides, alkyl maltopyranosides, glycerol fatty acid esters, alkyl benzene sulphonic acids, alkyl ether carboxylic acids, alkyl and aryl phosphate esters, alkyl and aryl sulfate esters, alkyl and aryl sulphonic acids, alkyl phenol phosphates esters, alkyl phenol sulfates esters, alkyl and aryl phosphates, alkyl polysaccharides, alkylamine ethoxylates, alkyl-naphthalene sulphonates formaldehyde condensates, sulfosuccinates, lignosulfonates, ceto-oleyl alcohol ethoxylates, condensed naphthalene sulphonates, dialkyl and alkyl naphthalene sulphonates, di-alkyl sulphosuccinates, ethoxylated nonylphenols, ethylene glycol esters, fatty alcohol alkoxylates, hydrogenated tallowalkylamines, mono-alkyl sulphosuccinamates, nonyl phenol ethoxylates, sodium oleyl N-methyl taurate, tallowalkylamines, linear and branched dodecylbenzene sulfonic acids.
In some embodiments, the facilitating agent is selected from the group consisting of sodium stearyl sulfate, sodium stearyl fumarate, magnesium stearate, talc, myristic acid, sodium cetyl sulfate, sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate, glycerol distearate glyceryl palmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate, benzalkonium chloride, cetyl trimethylammonium bromide, cetyl trimethylammonium chloride, cetrimide, cetylpyridinium chloride, cetylpyridinium bromide, benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188õ poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil, polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil, polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15 hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trioleate, sucrose palmitate, sucrose stearate, sucrose distearate, sucrose laurate, glycocholic acid, sodium glycholate, cholic acid, sodium cholate, sodium deoxycholate, deoxycholic acid, sodium taurocholate, taurocholic acid, sodium taurodeoxycholate, taurodeoxycholic acid, soy lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalene sulfonate condensate/lignosulfonate blend, calcium dodecylbenzene sulfonate, sodium dodecylbenzene sulfonate, diisopropyl naphthaenesulphonate, erythritol distearate, naphthalene sulfonate formaldehyde condensate, nonylphenol ethoxylate (POE-30), tristyrylphenol ethoxylate, polyoxyethylene (15) tallowalkylamines, sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonate condensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalene sulfonate, sodium methyl naphthalene formaldehyde sulfonate, sodium n-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18), triethanolamine isodecanol phosphate ester, triethanolamine tristyrylphosphate ester, tristyrylphenol ethoxylate sulfate, bis(2) hydroxyethyl)tallowalkylamines.
In some embodiments the facilitating agent is selected from the list of:
polyvinylpyrrolidones (PVP), polyvinylalcohol, acrylic acid based polymers and copolymers of acrylic acid.
In some embodiments, the facilitating agent has a concentration during dry milling selected from the group consisting of: 0.1 -10 % w/w, 0.1 -5 % w/w, 0.1 -2.5 % w/w, of 0.1 ¨
2% w/w, 0.1 -1 %, 0.5 -5% w/w, 0.5 -3% w/w, 0.5 -2% w/w, 0.5 ¨ 1.5%, 0.5 -1 % w/w, of 0.75 ¨
1.25 % w/w, 0.75 -1% and 1% w/w.
In some embodiments, a facilitating agent is used or combination of facilitating agents is used during dry milling. In some embodiments, the facilitating agent is added during dry milling. In some embodiments, the facilitating agent is added to the dry milling at a time selected from the group consisting of: with 1-5 % of the total milling time remaining, with 1-10 % of the total milling time remaining, with 1-20 % of the total milling time remaining, with 1-30 % of the total milling time remaining, with 2-5% of the total milling time remaining, with 2-10% of the total milling time remaining, with 5-20% of the total milling time remaining and with 5-20% of the total milling time remaining.
The reasons for including facilitating agents include, but are not limited to providing better dispersibility, control of agglomeration, the release or retention of the active particles from the delivery matrix. Examples of facilitating agents include, but are not limited to: sodium lauryl sulfate, cross-linked PVP (crospovidone), cross linked sodium carboxymethylcellulose (croscarmellose sodium), sodium starch glycolate, povidone (PVP), povidone K12, povidone K17, povidone K25, povidone K29/32 and povidone K30, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, sodium stearyl lactylate, zinc stearate, sodium stearate or lithium stearate, other solid state fatty acids such as oleic acid, lauric acid, palmitic acid, erucic acid, behenic acid, or derivatives (such as esters and salts), amino acids such as leucine, isoleucine, lysine, valine, methionine, phenylalanine, aspartame or acesulfame K.
In another aspect the disclosure includes a method of treating a human in need of such treatment comprising the step of administering to the human an effective amount of a pharmaceutical composition as described herein for treatment of castration resistant prostate cancer. The treatment can include administering 500mg of abiraterone acetate daily (e.g., in 1 or 2 or 4 equal doses (e.g., one unit dose containing 500mg, two unit doses containing 250mg of abiraterone acetate each, or four unit doses containing 125mg of abiraterone acetate each) . The patient can also be treated with a glucocorticoid, e.g, prednisone, dexamethasone or prednisolone (e.g., at 5 mg, twice daily). Alternatively, the patient can be treated with methylprednisolone (e.g. at 4 mg twice daily). The patient can also be treated with other chemotherapeutic agents or other agents for the treatment of cancer (e.g., prostate cancer).
The disclosure also includes a method for treating breast cancer (e.g., metastatic breast cancer) and ovarian cancer (e.g., epithelial ovarian cancer) using a composition described herein.
In another aspect, the disclosure comprises the use of a pharmaceutical composition as described herein in the manufacture of a medicament for the treatment of a human in need of such treatment.
In another aspect the disclosure comprises a method for manufacturing a pharmaceutical composition as described herein comprising the step of combining a composition comprising abiraterone acetate prepared by a method described herein or a composition as described herein, together with one of a diluent, lubricant, excipient, disintegrant, wetting agent, to produce a pharmaceutically acceptable dosage form.
The disclosure described herein may include one or more ranges of values (e.g.
size, concentration etc.). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range that lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
The entire disclosures of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference. Inclusion does not constitute an admission is made that any of the references constitute prior art or are part of the common general knowledge of those working in the field to which this disclosure relates.
Throughout this specification, unless the context requires otherwise, the word "comprise" or variations, such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer, or group of integers, but not the exclusion of any other integers or group of integers. It is also noted that in this disclosure, and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in US Patent law; e.g., they can mean "includes", "included", "including", and the like.
"Therapeutically effective amount" as used herein with respect to methods of treatment and in particular drug dosage, shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount,"
administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount"
by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
Throughout this specification, unless the context requires otherwise, the phrase "dry mill" or variations, such as "dry milling," should be understood to refer to milling in at least the substantial absence of liquids. If liquids are present, they are present in such amounts that the contents of the mill retain the characteristics of a dry powder.
The term "millable" means that the grinding matrix is capable of being reduced in size under the dry milling conditions of the method of the disclosure. In one embodiment of the disclosure, the milled grinding matrix is of a comparable particle size to the abiraterone acetate. In another embodiment of the disclosure the particle size of the matrix is substantially reduced but not as small as the abiraterone acetate.
Those skilled in the art will appreciate that the disclosure described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the steps, features, compositions and materials referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only.
Functionally equivalent products, compositions and methods are clearly within the scope of the disclosure as described herein.
Other aspects and advantages of the disclosure will become apparent to those skilled in the art from a review of the ensuing description.
Drawings Figure 1 is a graph of the results of particle size analysis of unmilled abiraterone acetate and abiraterone acetate in formula 1 and formula 2 of Example 1.
Figure 2 is a graph of the results of dissolution rate measurements for abiraterone acetate tablets as described in Example 3.
Figures 3A and 3B are graphs depicting the results of stability studies described in Example 6.
Detailed Description of the Disclosure Particle Size For measurements made using a laser diffraction the term "median particle size" is defined as the median particle diameter as determined on an equivalent spherical particle volume basis.
Where the term median is used, it is understood to describe the particle size that divides the population in half such that 50 % of the population on a volume basis is greater than or less than this size. The median particle size is written as: [D5o] or D[501 or [D50], D50, D(0.50) or D[0.5]
or similar. As used herein [D5o] or D[so] or [D50], D50, D(0.50) or D[0.5] or similar shall be taken to mean median particle size.
The term "Dx of the particle size distribution" refers to the xth percentile of the distribution on a volume basis; thus, D90 refers to the 90th percentile, D95 refers to the 95th percentile, and so forth. Taking D90 as an example this can often be written as, [D9o] or D[90]
or [D90], D(0.90) or D[0.9] or similar. With respect to the median particle size and Dx an upper case D or lowercase d are interchangeable and have the same meaning. Another commonly used way of describing a particle size distribution measured by laser diffraction, or an equivalent method known in the art, is to describe what % of a distribution is under or over a nominated size. The term "percentage less than" also written as "%<" is defined as the percentage, by volume, of a particle size distribution under a nominated size -for example the % < 1000 nm. The term "percentage greater than" also written as "%>" is defined as the percentage, by volume, of a particle size distribution over a nominated size -for example the %> 1000 nm. The term D(3,2) is referred to as the area-weighted mean size or the Sauter diameter; the term D(4,3) is referred to as the volume-weighted mean size. Detailed descriptions of how these values are calculated are known in the art and can be found in, for example, ISO 9276-2:2014(E).
For many of the materials subject to the methods of this disclosure the particle size can be easily measured. Where the active material has poor water solubility and the matrix it is milled in has good water solubility the powder can simply be dispersed in an aqueous solvent. In this scenario the matrix dissolves leaving the active material dispersed in the solvent.
This suspension can then be measured by techniques such as PCS or laser diffraction.
Suitable methods to measure an accurate particle size where the active material has substantive aqueous solubility or the matrix has low solubility in a water based dispersant are outlined below.
1. In the circumstance where an insoluble matrix such as microcrystalline cellulose prevents the measurement of the active material separation techniques such as filtration or centrifugation could be used to separate the insoluble matrix from the active material particles. Other ancillary techniques would also be required to determine if any active material was removed by the separation technique so that this could be taken into account.
2. In the case where the active material is too soluble in water, other solvents could be evaluated for the measurement of particle size. Where a solvent could be found that active material is poorly soluble in but is a good solvent for the matrix a measurement would be relatively straight forward. If such a solvent is difficult to find another approach would be to measure the ensemble of matrix and active material in a solvent (such as iso-octane) which both are insoluble in. Then the powder would be measured in another solvent where the active material is soluble but the matrix is not.
Thus with a measurement of the matrix particle size and a measurement of the size of the matrix and active material together an understanding of the active material particle size can be obtained.
3. In some circumstances image analysis could be used to obtain information about the particle size distribution of the active material. Suitable image measurement techniques might include transmission electron microscopy (TEM), scanning electron microscopy (SEM), optical microscopy and confocal microscopy. In addition to these standard techniques some additional technique would be required to be used in parallel to differentiate the active material and matrix particles. Depending on the chemical makeup of the materials involved possible techniques could be elemental analysis, Raman spectroscopy, FTIR spectroscopy or fluorescence spectroscopy.
Improving the dissolution profile The process results in the abiraterone acetate having an improved dissolution profile. An improved dissolution profile has significant advantages including, in some cases, the improvement of bioavailability of the abiraterone acetate in vivo. Standard methods for determining the dissolution profile of a material in vitro are available in the art. A suitable method to determine an improved dissolution profile in vitro may include determining the concentration of the sample material in a solution over a period of time and comparing the results from the sample material to a control sample. An observation that peak solution concentration for the sample material was achieved in less time than the control sample would indicate that the sample material has an improved dissolution profile. The test sample can be the unit dosage form containing abiraterone acetate with grinding matrix and/or other additives that has been subject to the processes of the disclosure described here, as well as excipients to manufacture the final dosage form. Herein a control sample can be as a physical of the components in the measurement sample with the same relative proportions of active, matrix and/or additive as the measurement sample. The control sample can also be the commercially available dosage form, ZytigaCD tablets, cut to represent an equivalent quantity of abirateratone acetate as the test sample. Standard methods for determining the improved dissolution profile of a material in vivo are available in the art.
Crystallization Profile Methods for determining the crystallinity profile of the abiraterone acetate are widely available in the art. Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
A morphicity Profile Methods for determining the amorphous content of the abiraterone acetate are widely available in the art. Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
Grinding Matrix As will be described subsequently, selection of an appropriate grinding matrix affords particular advantageous applications of the method of the present disclosure. Again, as will be described subsequently, a highly advantageous aspect of the present disclosure is that certain grinding matrixes appropriate for use in the method of the disclosure are also appropriate for use in a medicament. The present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and the grinding matrix or in some cases the abiraterone acetate and a portion of the grinding matrix, medicaments so produced, and methods of treatment using the medicament. The medicament may include only the milled abiraterone acetate together with the milled grinding matrix or, more preferably, the milled abiraterone acetate and milled grinding matrix may be combined with one or more pharmaceutically acceptable carriers, as well as any desired excipients or other like agents commonly used in the preparation of medicaments.
In some cases at least one component of the grinding matrix is harder than the abiraterone acetate, and is thus capable of reducing the particle size of the abiraterone acetate under the dry milling conditions of the disclosure. Again without wishing to be bound by theory, under these circumstances it is believed that the millable grinding matrix affords the advantage of the present disclosure through a second route, with the smaller particles of grinding matrix produced under the dry milling conditions enabling greater interaction with the abiraterone acetate.The quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of physical degradation of the grinding matrix, is sufficient to inhibit re-agglomeration of the particles of the active material In some embodiments, the quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of size reduction of the grinding matrix, is sufficient to inhibit re-agglomeration of the particles of the active material. As detailed above, the grinding matrix can include one or more anti-oxidants and/or one or more sequestering agents.
In some embodiments, the grinding matrix has a low tendency to agglomerate during dry milling. While it is difficult to objectively quantify the tendency to agglomerate during milling, it is possible to obtain a subjective measure by observing the level of "caking" of the grinding matrix in the milling chamber of the mill as dry milling progresses.
The grinding matrix may be an inorganic or organic substance.
Milling bodies In the method of the present disclosure, where milling bodies are utilized, the milling bodies are preferably chemically inert and rigid. The term "chemically-inert", as used herein, means that the milling bodies do not react chemically with the abiraterone acetate or the grinding matrix.
As described above, the milling bodies are essentially resistant to fracture and erosion in the milling process.
The milling bodies are desirably provided in the form of bodies which may have any of a variety of smooth, regular shapes, flat or curved surfaces, and lacking sharp or raised edges. For example, suitable milling bodies can be in the form of bodies having ellipsoidal, ovoid, spherical or right cylindrical shapes. In some embodiments, the milling bodies are provided in the form of one or more of beads, balls, spheres, rods, right cylinders, drums or radius-end right cylinders (i.e., right cylinders having hemispherical bases with the same radius as the cylinder).
Depending on the nature of the abiraterone acetate and the grinding matrix, the milling bodies desirably have an effective mean diameter between about 0.1 and 30 mm, more preferably between about 1 and about 15 mm, still more preferably between about 3 and 10 mm.
The milling bodies may comprise various substances such as ceramic, glass, metal or polymeric compositions, in a particulate form. Suitable metal milling bodies are typically spherical and generally have good hardness (i.e. RHC 60-70), roundness, high wear resistance, and narrow size distribution and can include, for example, balls fabricated from type 52100 chrome steel, type 304, 316 or 440C stainless steel or type 1065 high carbon steel.
Ceramics, for example, can be selected from a wide array of ceramics desirably having sufficient hardness and resistance to fracture to enable them to avoid being chipped or crushed during milling and also having sufficiently high density. Suitable densities for milling bodies can range from about 1 to 15 g/cm3, preferably from about 1 to 8 g/cm3. Ceramics can be selected from steatite, aluminum oxide, zirconium oxide, zirconia-silica, yttria-stabilized zirconium oxide, magnesia-stabilized zirconium oxide, silicon nitride, silicon carbide, cobalt-stabilized tungsten carbide, and the like, as well as mixtures thereof.
Glass milling bodies are spherical (e.g. beads), have a narrow size distribution, are durable, and include, for example, lead-free soda lime glass and borosilicate glass.
Polymeric milling bodies are preferably substantially spherical and can be selected from a wide array of polymeric resins having sufficient hardness and friability to enable them to avoid being chipped or crushed during milling, abrasion-resistance to minimize attrition resulting in contamination of the product, and freedom from impurities such as metals, solvents, and residual monomers.
Milling bodies can be formed from polymeric resins. Polymeric resins, for example, can be selected from crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene, styrene copolymers, polyacrylates such as polymethylmethacrylate, polycarbonates, polyacetals, vinyl chloride polymers and copolymers, polyurethanes, polyamides, high density polyethylenes, polypropylenes, and the like. The use of polymeric milling bodies to grind materials down to a very small particle size (as opposed to mechanochemical synthesis) is disclosed, for example, in U.S. patents 5,478,705 and 5,500,331. Polymeric resins typically can have densities ranging from about 0.8 to 3.0 g/cm3. Higher density polymeric resins are generally preferred.
Alternatively, the milling bodies can be composite bodies comprising dense core bodies having a polymeric resin adhered thereon. Core particles can be selected from substances known to be useful as milling bodies, for example, glass, alumina, zirconia silica, zirconium oxide, stainless steel, and the like. Core substances have densities greater than about 2.5 g/cm3.
In one embodiment of the disclosure, the milling bodies are formed from a ferromagnetic substance, thereby facilitating removal of contaminants arising from wear of the milling bodies by the use of magnetic separation techniques.
Each type of milling body has its own advantages. For example, metals have the highest specific gravities, which increase grinding efficiency due to increased impact energy.
Metal costs range from low to high, but metal contamination of final product can be an issue.
Glasses are advantageous from the standpoint of low cost and the availability of small bead sizes as low as 0.004 mm. However, the specific gravity of glasses is lower than other bodies and significantly more milling time is required. Finally, ceramics are advantageous from the standpoint of low wear and contamination, ease of cleaning, and high hardness.
Dry Milling In the dry milling process of the present disclosure, the abiraterone acetate and grinding matrix, in the form of crystals, powders, or the like, are combined in suitable proportions with or without a plurality of milling bodies in a milling chamber that is mechanically agitated for a predetermined period of time at a predetermined intensity of agitation.
Typically, a milling apparatus is used to impart motion to contents of the mill including any milling bodies by the external application of agitation, a stream of dry gas or other force, whereby various translational, rotational or inversion motions or combinations thereof are applied to the milling chamber and its contents, or by the internal application of agitation through a rotating shaft terminating in a blade, propeller, impeller or paddle or by a combination of both actions.
During milling, motion imparted to the milling bodies or gas flowing through the milling system can result in application of shearing forces as well as multiple impacts or collisions having significant intensity between the mill components, any milling bodies utilized and the particles of abiraterone acetate and the grinding matrix. The nature and intensity of the forces applied to the abiraterone acetate and the grinding matrix is influenced by a wide variety of processing parameters including: the type of milling apparatus; the intensity of the forces generated, the kinematic aspects of the process; the size, density, shape, and composition of any milling bodies used; the weight ratio of the abiraterone acetate and grinding matrix mixture to any milling bodies used; the duration of milling; the physical properties of both the abiraterone acetate and the grinding matrix; the atmosphere present during milling; and other factors.
Advantageously, the mill is capable of repeatedly or continuously applying mechanical compressive forces and shear stress to the abiraterone acetate and the grinding matrix.
Throughout the remainder of the specification reference will be made to dry milling being carried out by way of a ball mill. Examples of this type of mill are attritor mills, nutating mills, tower mills, planetary mills, vibratory mills, gravity-dependent-type ball mills, jet mills, rod mills, roller mills or crusher mills, jet mills and pulverizing mills. It will be appreciated that dry milling in accordance with the method of the disclosure may also be achieved by any suitable milling method or means.
In some cases, the particle size of the abiraterone acetate prior to dry milling according to the methods described herein is less than about 1000 pm, as determined by sieve analysis. If the particle size of the abiraterone acetate is greater than about 1000 p.m, then it is preferred that the particles of the abiraterone acetate substrate be reduced in size to less than 1000 p.m using another particle size reduction method prior to dry milling according to the methods described herein.
Agglomerates of abiraterone acetate after processing Agglomerates comprising particles of abiraterone acetate having a particle size within the ranges specified herein, should be understood to fall within the scope of the present disclosure, regardless of whether the agglomerates exceed the ranges specified above.
Processing Time In some embodiments, the abiraterone acetate and the grinding matrix are dry milled for the shortest time necessary to minimize any possible contamination from the mill process and/or any milling bodies utilized. This time varies greatly, depending on the abiraterone acetate and the grinding matrix, and may range from as short as 1 minute to several hours.
Suitable rates of agitation and total milling times are adjusted for the type and size of milling apparatus, the type and size of any milling media utilized, the weight ratio of the abiraterone acetate and grinding matrix mixture to the plurality of milling bodies that may be utilized, the chemical and physical properties of the abiraterone acetate and grinding matrix, and other parameters that may be optimized empirically.
In some embodiments, the grinding matrix (the materials milled together with abiraterone acetate) is not separated from the abiraterone acetate but is maintained with the abiraterone acetate in the final product. In some embodiments the grinding matrix is considered to be Generally Regarded as Safe (GRAS) for pharmaceutical products.
In an alternative aspect, the grinding matrix is separated from the abiraterone acetate. In one aspect, where the grinding matrix is not fully milled, the unmilled grinding matrix is separated from the abiraterone acetate. In a further aspect, at least a portion of the milled grinding matrix is separated from the abiraterone acetate.
Any portion of the grinding matrix may be removed, including but not limited to 10%, 25%, 50%, 75%, or substantially all of the grinding matrix.
In some embodiments of the disclosure, a significant portion of the milled grinding matrix may comprise particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate. Where the portion of the milled grinding matrix to be separated from the particles comprising the abiraterone acetate comprises particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate, separation techniques based on size distribution are inapplicable. In these circumstances, the method of the present disclosure may involve separation of at least a portion of the milled grinding matrix from the abiraterone acetate by techniques including, but not limited to, electrostatic separation, magnetic separation, centrifugation (density separation), hydrodynamic separation, and froth flotation.
Advantageously, the step of removing at least a portion of the milled grinding matrix from the abiraterone acetate may be performed through means such as selective dissolution, washing, or sublimation.
In some cases grinding matrix that has two or more components where at least one component is water soluble and at least one component has low solubility in water can be used. In this case washing can be used to remove the matrix component soluble in water leaving the abiraterone acetate dispersed in the remaining matrix components. In a highly advantageous aspect of the disclosure the matrix with low solubility is a functional excipient.
In some cases the grinding matrix is appropriate for use in the method of the disclosure are also pharmaceutically acceptable and thus appropriate for use in a medicament.
Where the method of the present disclosure does not involve complete separation of the grinding matrix from the abiraterone acetate, the present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and at least a portion of the milled grinding matrix, medicaments so produced and methods of treatment of an animal, including man, using a therapeutically effective amount of said abiraterone acetate by way of said medicaments.
Abiraterone acetate and compositions The present disclosure encompasses pharmaceutically acceptable materials produced according to the methods of the present disclosure, compositions including such materials, including compositions comprising such materials together with the grinding matrix with or without milling aids, facilitating agents, with at least a portion of the grinding matrix or separated from the grinding matrix.
Medicaments The medicaments of the present disclosure may include the pharmaceutically acceptable material, optionally together with the grinding matrix or at least a portion of the grinding matrix, with or without milling aids, facilitating agents, combined with one or more pharmaceutically acceptable carriers, as well as other agents commonly used in the preparation of pharmaceutically acceptable compositions.
As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In some embodiments, the carrier is suitable for parenteral administration, intravenous, intraperitoneal, intramuscular, sublingual, pulmonary, transdermal or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for the manufacture of medicaments is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutically acceptable material, use thereof in the manufacture of a pharmaceutical composition according to the disclosure is contemplated.
Pharmaceutical acceptable carriers according to the disclosure may include one or more of the following examples:
(1) surfactants and polymers including, but not limited to polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate, polyvinylalcohol, crospovidone, polyvinylpyrrolidone- polyvinylacrylate copolymer, cellulose derivatives, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethylethyl cellulose, hydroxypropyllmethyl cellulose phthalate, polyacrylates and polymethacrylates, urea, sugars, polyols, and their polymers, emulsifiers, sugar gum, starch, organic acids and their salts, vinyl pyrrolidone and vinyl acetate (2) binding agents such as various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose; and or (3) filling agents such as lactose monohydrate, lactose anhydrous, microcrystalline cellulose and various starches; and or (4) lubricating agents such as agents that act on the flowability of the powder to be compressed, including colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, silica gel; and or (5) sweeteners such as any natural or artificial sweetener including sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame K; and or
In some embodiments, the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: attritor mills (horizontal or vertical), nutating mills, tower mills, pearl mills, planetary mills, vibratory mills, eccentric vibratory mills, gravity-dependent-type ball mills, rod mills, roller mills and crusher mills. In some embodiments, the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: jet mills, spiral jet mills, micronisers or pulverizers. Preferably, the method is configured to produce the abiraterone acetate in a swing batch or continuous fashion.
In some embodiments, where a mill uses milling bodies, the milling bodies within the milling apparatus are mechanically agitated by 1, 2 or 3 rotating shafts. The milling bodies can be formed of a material selected from the group consisting of: ceramics, glasses, steels, polymers, ferromagnetics and metals and other suitable materials. In some embodiments, the milling bodies are steel balls having a diameter selected from the group consisting of:
between 1 and 20 mm, between 2 and 15 mm and between 3 and 10 mm. In various embodiments of the dry milling method, the milling bodies are zirconium oxide balls having a diameter selected from the group consisting of: between 1 and 20 mm, between 2 and 15 mm and between 3 and 10 mm.
In another embodiment, the milling time period is a range selected from the group consisting of:
between 10 minutes and 6 hours, between 10 minutes and 2 hours, between 10 minutes and 90 minutes, between 10 minutes and 1 hour, between 10 minutes and 45 minutes, between 10 minutes and 30 minutes, between 5 minutes and 30 minutes, between 5 minutes and 20 minutes, between 2 minutes and 10 minutes, between 2 minutes and 5 minutes, between 1 minutes and 2 minutes.
Additional Milling Matrixes and Facilitating Agents In embodiments, the grinding matrix is a single material or is a mixture of two or more materials in any proportion. In some embodiments, the single material or a mixture of two or more materials is selected from the group consisting of: mannitol, sorbitol, isomalt, xylitol, maltitol, lactitol, erythritol, arabitol, ribitol, glucose, fructose, mannose, galactose, anhydrous lactose, lactose monohydrate, sucrose, maltose, trehalose, and maltodextrins. In some embodiments the single material or mixture of two or more materials is selected from the group consisting of:
dextrin, inulin, dextrates, polydextrose, starch, wheat flour, corn flour, rice flour, rice starch, tapioca flour, tapioca starch, potato flour, potato starch, other flours and starches, milk powder, skim milk powders, other milk solids and derivatives, soy flour, soy meal or other soy products, cellulose, microcrystalline cellulose, microcrystalline cellulose based co-blended materials, pregelatinized (or partially gelatinized) starch, hypromellose, carboxymethyl cellulose, hydroxypropyl cellulose, citric acid, tartaric acid, malic acid, maleic acid, fumaric acid, ascorbic acid, succinic acid, sodium citrate, sodium tartrate, sodium malate, sodium ascorbate, potassium citrate, potassium tartrate, potassium malate, sodium acetate, potassium ascorbate, sodium carbonate, potassium carbonate, magnesium carbonate, sodium bicarbonate, potassium bicarbonate, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, sodium sulfate, sodium chloride, sodium metabisulphite, sodium thiosulfate, ammonium chloride, glauber's salt, ammonium carbonate, sodium bisulfate, magnesium sulfate, potash alum, potassium chloride, sodium hydrogen sulfate, sodium hydroxide, crystalline hydroxides, hydrogen carbonates, ammonium chloride, methylamine hydrochloride, ammonium bromide, silica, thermal silica, alumina, titanium dioxide, talc, chalk, mica, kaolin, bentonite, hectorite, magnesium trisilicate, clay based materials or aluminium silicates, sodium lauryl sulfate, sodium stearyl sulfate, sodium cetyl sulfate, sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate, glycerol distearate glyceryl palmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate, benzalkonium chloride, cetrimonium bromide, cetrimonium chloride, cetrimide, cetylpyridinium chloride, cetylpyridinium bromide, benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil, polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil, polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15 hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trioleate, sucrose palmitate, sucrose stearate, sucrose distearate, sucrose laurate, glycocholic acid, sodium glycholate, cholic acid, sodium cholate, sodium deoxycholate, deoxycholic acid, sodium taurocholate, taurocholic acid, sodium taurodeoxycholate, taurodeoxycholic acid, soy lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalene sulfonate condensate/Lignosulfonate blend, calcium dodecylbenzene sulfonate, sodium dodecylbenzene sulfonate, diisopropyl naphthaenesulphonate, erythritol distearate, naphthalene sulfonate formaldehyde condensate, nonylphenol ethoxylate (poe-30), tristyrylphenol ethoxylate, polyoxyethylene (15) tallowalkylamines, sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonate condensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalene sulfonate, sodium methyl naphthalene formaldehyde sulfonate, sodium n-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18), triethanolamine isodecanol phosphate ester, triethanolamine tristyrylphosphate ester, tristyrylphenol ethoxylate sulfate, bis(2-hydroxyethyl)tallowalkylamines.
In some embodiments, the concentration of the single (or first) component of the grinding matrix is selected from the group consisting of: 5 - 99 % w/w, 10 - 95 % w/w, 15 - 85 % w/w, of 20 ¨
80% w/w, 25 - 75 % w/w, 30 - 60% w/w, 40 -50% w/w. In some embodiments, the concentration of the second or subsequent component of the grinding matrix is selected from the group consisting of: 5 - 50 % w/w, 5 - 40 % w/w, 5 - 30 % w/w, of 5 ¨ 20% w/w, 10 - 40 %
w/w, 10 -30% w/w, 10 -20% w/w, 20 - 40% w/w, or 20 - 30% w/w or if the second or subsequent material is a surfactant or water soluble polymer the concentration is selected from 0.1 -10 % w/w, 0.1-5 % w/w, 0.1 -2.5 % w/w, of 0.1 ¨2% w/w, 0.1 -1 %, 0.5 -5%w/w, 0.5 -3%
w/w, 0.5 -2% w/w, 0.5 ¨ 1.5%, 0.5 -1 % w/w, of 0.75 ¨ 1.25 % w/w, 0.75 -1% and 1% w/w.
In some embodiments, abiraterone acetate is milled in the presence of:
(a) Lactose monohydrate or lactose monohydrate combined with at least one material selected from the group consisting of: xylitol; lactose anhydrous;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(b) Lactose anhydrous or lactose anhydrous combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(c) Mannitol or mannitol combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; lactose anhydrous;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
(d) Sucrose or sucrose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(e) Glucose or glucose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(f) Sodium chloride or sodium chloride combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous;
mannitol;
microcrystalline cellulose; sucrose; glucose; talc; kaolin; calcium carbonate;
malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde Sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(g) Xylitol or xylitol combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate;
malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(h) Tartaric acid or tartaric acid combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol;
microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin;
calcium carbonate; malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and Polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; Phosphate Esters, tristyrylphenol Ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(i) Microcrystalline cellulose or microcrystalline cellulose combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol;
lactose anhydrous; mannitol; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid;
sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether;
polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium;
polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG
3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and Polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate;
erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines;
sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate;
sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(j) Kaolin combined with at least one material selected from the group consisting of:
lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystalline cellulose;
sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; Polyoxyl 100 stearyl ether; Polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
Hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched); diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate; nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene; formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate;
tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester;
briethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate;
bis(2-hydroxyethyl)tallowalkylamines.
(k) Talc combined with at least one material selected from the group consisting of:
lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystalline cellulose;
sucrose; glucose; sodium chloride; kaolin; calcium carbonate; malic acid;
tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate;
sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether;
sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG
6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl naphthalene sulfonate condensate/lignosulfonate blend; calcium dodecylbenzene sulfonate (branched);
diisopropyl naphthalenesulphonate; erythritol distearate; linear and branched dodecylbenzene sulfonic acids; naphthalene sulfonate formaldehyde condensate;
nonylphenol ethoxylate, POE-30; phosphate esters, tristyrylphenol ethoxylate, free acid; polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene sulfonate;
sodium alkyl naphthalene sulfonate condensate; sodium alkylbenzene sulfonate;
sodium isopropyl naphthalene sulfonate; sodium methyl naphthalene;
formaldehyde sulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18; triethanolamine isodecanol phosphate ester; triethanolamine tristyrylphosphate ester; tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines.
In some embodiments, the abiraterone acetate is dry milled with one or more additional materials is selected from the group consisting of: a material considered to be 'Generally Regarded as Safe' (GRAS) for pharmaceutical products.
In some embodiments, the dry milling of abiraterone acetate takes place in the presence of a facilitating agent or combination of facilitating agents. In some embodiments, the facilitating agent is selected from the group consisting of: a glidant, a surfactant, a polymer, and/or a lubricant. In some embodiments, the facilitating agent is selected from the group consisting of:
colloidal silicon dioxide, sodium stearate and talc. In some embodiments, the facilitating agent is selected from the group consisting of: benzethonium chloride, docusate sodium, polyethylene alkyl ethers, sodium lauryl sulfate, tricaprylin, alpha tocopherol, glyceryl monooleate, myristyl alcohol, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene stearates, polyoxyethylene castor oil derivatives, polyoxyl 15 hydroxystearate, polyoxylglycerides, polysorbates, propylene glycol dilaurate, sorbitan esters, sucrose palmitate, vitamin E polyethylene glycol succinate, polyethylene glycols (PEG), poloxamers, poloxamines, sarcosine based surfactants, polysorbates, aliphatic alcohols, alkyl and aryl sulfates, alkyl and aryl polyether sulfonates and other sulfate surfactants, trimethyl ammonium based surfactants, lecithin and other phospholipids, bile salts, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters sucrose fatty acid esters, alkyl glucopyranosides, alkyl maltopyranosides, glycerol fatty acid esters, alkyl benzene sulphonic acids, alkyl ether carboxylic acids, alkyl and aryl phosphate esters, alkyl and aryl sulfate esters, alkyl and aryl sulphonic acids, alkyl phenol phosphates esters, alkyl phenol sulfates esters, alkyl and aryl phosphates, alkyl polysaccharides, alkylamine ethoxylates, alkyl-naphthalene sulphonates formaldehyde condensates, sulfosuccinates, lignosulfonates, ceto-oleyl alcohol ethoxylates, condensed naphthalene sulphonates, dialkyl and alkyl naphthalene sulphonates, di-alkyl sulphosuccinates, ethoxylated nonylphenols, ethylene glycol esters, fatty alcohol alkoxylates, hydrogenated tallowalkylamines, mono-alkyl sulphosuccinamates, nonyl phenol ethoxylates, sodium oleyl N-methyl taurate, tallowalkylamines, linear and branched dodecylbenzene sulfonic acids.
In some embodiments, the facilitating agent is selected from the group consisting of sodium stearyl sulfate, sodium stearyl fumarate, magnesium stearate, talc, myristic acid, sodium cetyl sulfate, sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate, glycerol distearate glyceryl palmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate, benzalkonium chloride, cetyl trimethylammonium bromide, cetyl trimethylammonium chloride, cetrimide, cetylpyridinium chloride, cetylpyridinium bromide, benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188õ poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil, polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil, polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15 hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trioleate, sucrose palmitate, sucrose stearate, sucrose distearate, sucrose laurate, glycocholic acid, sodium glycholate, cholic acid, sodium cholate, sodium deoxycholate, deoxycholic acid, sodium taurocholate, taurocholic acid, sodium taurodeoxycholate, taurodeoxycholic acid, soy lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalene sulfonate condensate/lignosulfonate blend, calcium dodecylbenzene sulfonate, sodium dodecylbenzene sulfonate, diisopropyl naphthaenesulphonate, erythritol distearate, naphthalene sulfonate formaldehyde condensate, nonylphenol ethoxylate (POE-30), tristyrylphenol ethoxylate, polyoxyethylene (15) tallowalkylamines, sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonate condensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalene sulfonate, sodium methyl naphthalene formaldehyde sulfonate, sodium n-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18), triethanolamine isodecanol phosphate ester, triethanolamine tristyrylphosphate ester, tristyrylphenol ethoxylate sulfate, bis(2) hydroxyethyl)tallowalkylamines.
In some embodiments the facilitating agent is selected from the list of:
polyvinylpyrrolidones (PVP), polyvinylalcohol, acrylic acid based polymers and copolymers of acrylic acid.
In some embodiments, the facilitating agent has a concentration during dry milling selected from the group consisting of: 0.1 -10 % w/w, 0.1 -5 % w/w, 0.1 -2.5 % w/w, of 0.1 ¨
2% w/w, 0.1 -1 %, 0.5 -5% w/w, 0.5 -3% w/w, 0.5 -2% w/w, 0.5 ¨ 1.5%, 0.5 -1 % w/w, of 0.75 ¨
1.25 % w/w, 0.75 -1% and 1% w/w.
In some embodiments, a facilitating agent is used or combination of facilitating agents is used during dry milling. In some embodiments, the facilitating agent is added during dry milling. In some embodiments, the facilitating agent is added to the dry milling at a time selected from the group consisting of: with 1-5 % of the total milling time remaining, with 1-10 % of the total milling time remaining, with 1-20 % of the total milling time remaining, with 1-30 % of the total milling time remaining, with 2-5% of the total milling time remaining, with 2-10% of the total milling time remaining, with 5-20% of the total milling time remaining and with 5-20% of the total milling time remaining.
The reasons for including facilitating agents include, but are not limited to providing better dispersibility, control of agglomeration, the release or retention of the active particles from the delivery matrix. Examples of facilitating agents include, but are not limited to: sodium lauryl sulfate, cross-linked PVP (crospovidone), cross linked sodium carboxymethylcellulose (croscarmellose sodium), sodium starch glycolate, povidone (PVP), povidone K12, povidone K17, povidone K25, povidone K29/32 and povidone K30, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, sodium stearyl lactylate, zinc stearate, sodium stearate or lithium stearate, other solid state fatty acids such as oleic acid, lauric acid, palmitic acid, erucic acid, behenic acid, or derivatives (such as esters and salts), amino acids such as leucine, isoleucine, lysine, valine, methionine, phenylalanine, aspartame or acesulfame K.
In another aspect the disclosure includes a method of treating a human in need of such treatment comprising the step of administering to the human an effective amount of a pharmaceutical composition as described herein for treatment of castration resistant prostate cancer. The treatment can include administering 500mg of abiraterone acetate daily (e.g., in 1 or 2 or 4 equal doses (e.g., one unit dose containing 500mg, two unit doses containing 250mg of abiraterone acetate each, or four unit doses containing 125mg of abiraterone acetate each) . The patient can also be treated with a glucocorticoid, e.g, prednisone, dexamethasone or prednisolone (e.g., at 5 mg, twice daily). Alternatively, the patient can be treated with methylprednisolone (e.g. at 4 mg twice daily). The patient can also be treated with other chemotherapeutic agents or other agents for the treatment of cancer (e.g., prostate cancer).
The disclosure also includes a method for treating breast cancer (e.g., metastatic breast cancer) and ovarian cancer (e.g., epithelial ovarian cancer) using a composition described herein.
In another aspect, the disclosure comprises the use of a pharmaceutical composition as described herein in the manufacture of a medicament for the treatment of a human in need of such treatment.
In another aspect the disclosure comprises a method for manufacturing a pharmaceutical composition as described herein comprising the step of combining a composition comprising abiraterone acetate prepared by a method described herein or a composition as described herein, together with one of a diluent, lubricant, excipient, disintegrant, wetting agent, to produce a pharmaceutically acceptable dosage form.
The disclosure described herein may include one or more ranges of values (e.g.
size, concentration etc.). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range that lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
The entire disclosures of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference. Inclusion does not constitute an admission is made that any of the references constitute prior art or are part of the common general knowledge of those working in the field to which this disclosure relates.
Throughout this specification, unless the context requires otherwise, the word "comprise" or variations, such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer, or group of integers, but not the exclusion of any other integers or group of integers. It is also noted that in this disclosure, and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in US Patent law; e.g., they can mean "includes", "included", "including", and the like.
"Therapeutically effective amount" as used herein with respect to methods of treatment and in particular drug dosage, shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount,"
administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount"
by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
Throughout this specification, unless the context requires otherwise, the phrase "dry mill" or variations, such as "dry milling," should be understood to refer to milling in at least the substantial absence of liquids. If liquids are present, they are present in such amounts that the contents of the mill retain the characteristics of a dry powder.
The term "millable" means that the grinding matrix is capable of being reduced in size under the dry milling conditions of the method of the disclosure. In one embodiment of the disclosure, the milled grinding matrix is of a comparable particle size to the abiraterone acetate. In another embodiment of the disclosure the particle size of the matrix is substantially reduced but not as small as the abiraterone acetate.
Those skilled in the art will appreciate that the disclosure described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the steps, features, compositions and materials referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only.
Functionally equivalent products, compositions and methods are clearly within the scope of the disclosure as described herein.
Other aspects and advantages of the disclosure will become apparent to those skilled in the art from a review of the ensuing description.
Drawings Figure 1 is a graph of the results of particle size analysis of unmilled abiraterone acetate and abiraterone acetate in formula 1 and formula 2 of Example 1.
Figure 2 is a graph of the results of dissolution rate measurements for abiraterone acetate tablets as described in Example 3.
Figures 3A and 3B are graphs depicting the results of stability studies described in Example 6.
Detailed Description of the Disclosure Particle Size For measurements made using a laser diffraction the term "median particle size" is defined as the median particle diameter as determined on an equivalent spherical particle volume basis.
Where the term median is used, it is understood to describe the particle size that divides the population in half such that 50 % of the population on a volume basis is greater than or less than this size. The median particle size is written as: [D5o] or D[501 or [D50], D50, D(0.50) or D[0.5]
or similar. As used herein [D5o] or D[so] or [D50], D50, D(0.50) or D[0.5] or similar shall be taken to mean median particle size.
The term "Dx of the particle size distribution" refers to the xth percentile of the distribution on a volume basis; thus, D90 refers to the 90th percentile, D95 refers to the 95th percentile, and so forth. Taking D90 as an example this can often be written as, [D9o] or D[90]
or [D90], D(0.90) or D[0.9] or similar. With respect to the median particle size and Dx an upper case D or lowercase d are interchangeable and have the same meaning. Another commonly used way of describing a particle size distribution measured by laser diffraction, or an equivalent method known in the art, is to describe what % of a distribution is under or over a nominated size. The term "percentage less than" also written as "%<" is defined as the percentage, by volume, of a particle size distribution under a nominated size -for example the % < 1000 nm. The term "percentage greater than" also written as "%>" is defined as the percentage, by volume, of a particle size distribution over a nominated size -for example the %> 1000 nm. The term D(3,2) is referred to as the area-weighted mean size or the Sauter diameter; the term D(4,3) is referred to as the volume-weighted mean size. Detailed descriptions of how these values are calculated are known in the art and can be found in, for example, ISO 9276-2:2014(E).
For many of the materials subject to the methods of this disclosure the particle size can be easily measured. Where the active material has poor water solubility and the matrix it is milled in has good water solubility the powder can simply be dispersed in an aqueous solvent. In this scenario the matrix dissolves leaving the active material dispersed in the solvent.
This suspension can then be measured by techniques such as PCS or laser diffraction.
Suitable methods to measure an accurate particle size where the active material has substantive aqueous solubility or the matrix has low solubility in a water based dispersant are outlined below.
1. In the circumstance where an insoluble matrix such as microcrystalline cellulose prevents the measurement of the active material separation techniques such as filtration or centrifugation could be used to separate the insoluble matrix from the active material particles. Other ancillary techniques would also be required to determine if any active material was removed by the separation technique so that this could be taken into account.
2. In the case where the active material is too soluble in water, other solvents could be evaluated for the measurement of particle size. Where a solvent could be found that active material is poorly soluble in but is a good solvent for the matrix a measurement would be relatively straight forward. If such a solvent is difficult to find another approach would be to measure the ensemble of matrix and active material in a solvent (such as iso-octane) which both are insoluble in. Then the powder would be measured in another solvent where the active material is soluble but the matrix is not.
Thus with a measurement of the matrix particle size and a measurement of the size of the matrix and active material together an understanding of the active material particle size can be obtained.
3. In some circumstances image analysis could be used to obtain information about the particle size distribution of the active material. Suitable image measurement techniques might include transmission electron microscopy (TEM), scanning electron microscopy (SEM), optical microscopy and confocal microscopy. In addition to these standard techniques some additional technique would be required to be used in parallel to differentiate the active material and matrix particles. Depending on the chemical makeup of the materials involved possible techniques could be elemental analysis, Raman spectroscopy, FTIR spectroscopy or fluorescence spectroscopy.
Improving the dissolution profile The process results in the abiraterone acetate having an improved dissolution profile. An improved dissolution profile has significant advantages including, in some cases, the improvement of bioavailability of the abiraterone acetate in vivo. Standard methods for determining the dissolution profile of a material in vitro are available in the art. A suitable method to determine an improved dissolution profile in vitro may include determining the concentration of the sample material in a solution over a period of time and comparing the results from the sample material to a control sample. An observation that peak solution concentration for the sample material was achieved in less time than the control sample would indicate that the sample material has an improved dissolution profile. The test sample can be the unit dosage form containing abiraterone acetate with grinding matrix and/or other additives that has been subject to the processes of the disclosure described here, as well as excipients to manufacture the final dosage form. Herein a control sample can be as a physical of the components in the measurement sample with the same relative proportions of active, matrix and/or additive as the measurement sample. The control sample can also be the commercially available dosage form, ZytigaCD tablets, cut to represent an equivalent quantity of abirateratone acetate as the test sample. Standard methods for determining the improved dissolution profile of a material in vivo are available in the art.
Crystallization Profile Methods for determining the crystallinity profile of the abiraterone acetate are widely available in the art. Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
A morphicity Profile Methods for determining the amorphous content of the abiraterone acetate are widely available in the art. Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
Grinding Matrix As will be described subsequently, selection of an appropriate grinding matrix affords particular advantageous applications of the method of the present disclosure. Again, as will be described subsequently, a highly advantageous aspect of the present disclosure is that certain grinding matrixes appropriate for use in the method of the disclosure are also appropriate for use in a medicament. The present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and the grinding matrix or in some cases the abiraterone acetate and a portion of the grinding matrix, medicaments so produced, and methods of treatment using the medicament. The medicament may include only the milled abiraterone acetate together with the milled grinding matrix or, more preferably, the milled abiraterone acetate and milled grinding matrix may be combined with one or more pharmaceutically acceptable carriers, as well as any desired excipients or other like agents commonly used in the preparation of medicaments.
In some cases at least one component of the grinding matrix is harder than the abiraterone acetate, and is thus capable of reducing the particle size of the abiraterone acetate under the dry milling conditions of the disclosure. Again without wishing to be bound by theory, under these circumstances it is believed that the millable grinding matrix affords the advantage of the present disclosure through a second route, with the smaller particles of grinding matrix produced under the dry milling conditions enabling greater interaction with the abiraterone acetate.The quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of physical degradation of the grinding matrix, is sufficient to inhibit re-agglomeration of the particles of the active material In some embodiments, the quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of size reduction of the grinding matrix, is sufficient to inhibit re-agglomeration of the particles of the active material. As detailed above, the grinding matrix can include one or more anti-oxidants and/or one or more sequestering agents.
In some embodiments, the grinding matrix has a low tendency to agglomerate during dry milling. While it is difficult to objectively quantify the tendency to agglomerate during milling, it is possible to obtain a subjective measure by observing the level of "caking" of the grinding matrix in the milling chamber of the mill as dry milling progresses.
The grinding matrix may be an inorganic or organic substance.
Milling bodies In the method of the present disclosure, where milling bodies are utilized, the milling bodies are preferably chemically inert and rigid. The term "chemically-inert", as used herein, means that the milling bodies do not react chemically with the abiraterone acetate or the grinding matrix.
As described above, the milling bodies are essentially resistant to fracture and erosion in the milling process.
The milling bodies are desirably provided in the form of bodies which may have any of a variety of smooth, regular shapes, flat or curved surfaces, and lacking sharp or raised edges. For example, suitable milling bodies can be in the form of bodies having ellipsoidal, ovoid, spherical or right cylindrical shapes. In some embodiments, the milling bodies are provided in the form of one or more of beads, balls, spheres, rods, right cylinders, drums or radius-end right cylinders (i.e., right cylinders having hemispherical bases with the same radius as the cylinder).
Depending on the nature of the abiraterone acetate and the grinding matrix, the milling bodies desirably have an effective mean diameter between about 0.1 and 30 mm, more preferably between about 1 and about 15 mm, still more preferably between about 3 and 10 mm.
The milling bodies may comprise various substances such as ceramic, glass, metal or polymeric compositions, in a particulate form. Suitable metal milling bodies are typically spherical and generally have good hardness (i.e. RHC 60-70), roundness, high wear resistance, and narrow size distribution and can include, for example, balls fabricated from type 52100 chrome steel, type 304, 316 or 440C stainless steel or type 1065 high carbon steel.
Ceramics, for example, can be selected from a wide array of ceramics desirably having sufficient hardness and resistance to fracture to enable them to avoid being chipped or crushed during milling and also having sufficiently high density. Suitable densities for milling bodies can range from about 1 to 15 g/cm3, preferably from about 1 to 8 g/cm3. Ceramics can be selected from steatite, aluminum oxide, zirconium oxide, zirconia-silica, yttria-stabilized zirconium oxide, magnesia-stabilized zirconium oxide, silicon nitride, silicon carbide, cobalt-stabilized tungsten carbide, and the like, as well as mixtures thereof.
Glass milling bodies are spherical (e.g. beads), have a narrow size distribution, are durable, and include, for example, lead-free soda lime glass and borosilicate glass.
Polymeric milling bodies are preferably substantially spherical and can be selected from a wide array of polymeric resins having sufficient hardness and friability to enable them to avoid being chipped or crushed during milling, abrasion-resistance to minimize attrition resulting in contamination of the product, and freedom from impurities such as metals, solvents, and residual monomers.
Milling bodies can be formed from polymeric resins. Polymeric resins, for example, can be selected from crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene, styrene copolymers, polyacrylates such as polymethylmethacrylate, polycarbonates, polyacetals, vinyl chloride polymers and copolymers, polyurethanes, polyamides, high density polyethylenes, polypropylenes, and the like. The use of polymeric milling bodies to grind materials down to a very small particle size (as opposed to mechanochemical synthesis) is disclosed, for example, in U.S. patents 5,478,705 and 5,500,331. Polymeric resins typically can have densities ranging from about 0.8 to 3.0 g/cm3. Higher density polymeric resins are generally preferred.
Alternatively, the milling bodies can be composite bodies comprising dense core bodies having a polymeric resin adhered thereon. Core particles can be selected from substances known to be useful as milling bodies, for example, glass, alumina, zirconia silica, zirconium oxide, stainless steel, and the like. Core substances have densities greater than about 2.5 g/cm3.
In one embodiment of the disclosure, the milling bodies are formed from a ferromagnetic substance, thereby facilitating removal of contaminants arising from wear of the milling bodies by the use of magnetic separation techniques.
Each type of milling body has its own advantages. For example, metals have the highest specific gravities, which increase grinding efficiency due to increased impact energy.
Metal costs range from low to high, but metal contamination of final product can be an issue.
Glasses are advantageous from the standpoint of low cost and the availability of small bead sizes as low as 0.004 mm. However, the specific gravity of glasses is lower than other bodies and significantly more milling time is required. Finally, ceramics are advantageous from the standpoint of low wear and contamination, ease of cleaning, and high hardness.
Dry Milling In the dry milling process of the present disclosure, the abiraterone acetate and grinding matrix, in the form of crystals, powders, or the like, are combined in suitable proportions with or without a plurality of milling bodies in a milling chamber that is mechanically agitated for a predetermined period of time at a predetermined intensity of agitation.
Typically, a milling apparatus is used to impart motion to contents of the mill including any milling bodies by the external application of agitation, a stream of dry gas or other force, whereby various translational, rotational or inversion motions or combinations thereof are applied to the milling chamber and its contents, or by the internal application of agitation through a rotating shaft terminating in a blade, propeller, impeller or paddle or by a combination of both actions.
During milling, motion imparted to the milling bodies or gas flowing through the milling system can result in application of shearing forces as well as multiple impacts or collisions having significant intensity between the mill components, any milling bodies utilized and the particles of abiraterone acetate and the grinding matrix. The nature and intensity of the forces applied to the abiraterone acetate and the grinding matrix is influenced by a wide variety of processing parameters including: the type of milling apparatus; the intensity of the forces generated, the kinematic aspects of the process; the size, density, shape, and composition of any milling bodies used; the weight ratio of the abiraterone acetate and grinding matrix mixture to any milling bodies used; the duration of milling; the physical properties of both the abiraterone acetate and the grinding matrix; the atmosphere present during milling; and other factors.
Advantageously, the mill is capable of repeatedly or continuously applying mechanical compressive forces and shear stress to the abiraterone acetate and the grinding matrix.
Throughout the remainder of the specification reference will be made to dry milling being carried out by way of a ball mill. Examples of this type of mill are attritor mills, nutating mills, tower mills, planetary mills, vibratory mills, gravity-dependent-type ball mills, jet mills, rod mills, roller mills or crusher mills, jet mills and pulverizing mills. It will be appreciated that dry milling in accordance with the method of the disclosure may also be achieved by any suitable milling method or means.
In some cases, the particle size of the abiraterone acetate prior to dry milling according to the methods described herein is less than about 1000 pm, as determined by sieve analysis. If the particle size of the abiraterone acetate is greater than about 1000 p.m, then it is preferred that the particles of the abiraterone acetate substrate be reduced in size to less than 1000 p.m using another particle size reduction method prior to dry milling according to the methods described herein.
Agglomerates of abiraterone acetate after processing Agglomerates comprising particles of abiraterone acetate having a particle size within the ranges specified herein, should be understood to fall within the scope of the present disclosure, regardless of whether the agglomerates exceed the ranges specified above.
Processing Time In some embodiments, the abiraterone acetate and the grinding matrix are dry milled for the shortest time necessary to minimize any possible contamination from the mill process and/or any milling bodies utilized. This time varies greatly, depending on the abiraterone acetate and the grinding matrix, and may range from as short as 1 minute to several hours.
Suitable rates of agitation and total milling times are adjusted for the type and size of milling apparatus, the type and size of any milling media utilized, the weight ratio of the abiraterone acetate and grinding matrix mixture to the plurality of milling bodies that may be utilized, the chemical and physical properties of the abiraterone acetate and grinding matrix, and other parameters that may be optimized empirically.
In some embodiments, the grinding matrix (the materials milled together with abiraterone acetate) is not separated from the abiraterone acetate but is maintained with the abiraterone acetate in the final product. In some embodiments the grinding matrix is considered to be Generally Regarded as Safe (GRAS) for pharmaceutical products.
In an alternative aspect, the grinding matrix is separated from the abiraterone acetate. In one aspect, where the grinding matrix is not fully milled, the unmilled grinding matrix is separated from the abiraterone acetate. In a further aspect, at least a portion of the milled grinding matrix is separated from the abiraterone acetate.
Any portion of the grinding matrix may be removed, including but not limited to 10%, 25%, 50%, 75%, or substantially all of the grinding matrix.
In some embodiments of the disclosure, a significant portion of the milled grinding matrix may comprise particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate. Where the portion of the milled grinding matrix to be separated from the particles comprising the abiraterone acetate comprises particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate, separation techniques based on size distribution are inapplicable. In these circumstances, the method of the present disclosure may involve separation of at least a portion of the milled grinding matrix from the abiraterone acetate by techniques including, but not limited to, electrostatic separation, magnetic separation, centrifugation (density separation), hydrodynamic separation, and froth flotation.
Advantageously, the step of removing at least a portion of the milled grinding matrix from the abiraterone acetate may be performed through means such as selective dissolution, washing, or sublimation.
In some cases grinding matrix that has two or more components where at least one component is water soluble and at least one component has low solubility in water can be used. In this case washing can be used to remove the matrix component soluble in water leaving the abiraterone acetate dispersed in the remaining matrix components. In a highly advantageous aspect of the disclosure the matrix with low solubility is a functional excipient.
In some cases the grinding matrix is appropriate for use in the method of the disclosure are also pharmaceutically acceptable and thus appropriate for use in a medicament.
Where the method of the present disclosure does not involve complete separation of the grinding matrix from the abiraterone acetate, the present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and at least a portion of the milled grinding matrix, medicaments so produced and methods of treatment of an animal, including man, using a therapeutically effective amount of said abiraterone acetate by way of said medicaments.
Abiraterone acetate and compositions The present disclosure encompasses pharmaceutically acceptable materials produced according to the methods of the present disclosure, compositions including such materials, including compositions comprising such materials together with the grinding matrix with or without milling aids, facilitating agents, with at least a portion of the grinding matrix or separated from the grinding matrix.
Medicaments The medicaments of the present disclosure may include the pharmaceutically acceptable material, optionally together with the grinding matrix or at least a portion of the grinding matrix, with or without milling aids, facilitating agents, combined with one or more pharmaceutically acceptable carriers, as well as other agents commonly used in the preparation of pharmaceutically acceptable compositions.
As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In some embodiments, the carrier is suitable for parenteral administration, intravenous, intraperitoneal, intramuscular, sublingual, pulmonary, transdermal or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for the manufacture of medicaments is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutically acceptable material, use thereof in the manufacture of a pharmaceutical composition according to the disclosure is contemplated.
Pharmaceutical acceptable carriers according to the disclosure may include one or more of the following examples:
(1) surfactants and polymers including, but not limited to polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate, polyvinylalcohol, crospovidone, polyvinylpyrrolidone- polyvinylacrylate copolymer, cellulose derivatives, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethylethyl cellulose, hydroxypropyllmethyl cellulose phthalate, polyacrylates and polymethacrylates, urea, sugars, polyols, and their polymers, emulsifiers, sugar gum, starch, organic acids and their salts, vinyl pyrrolidone and vinyl acetate (2) binding agents such as various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose; and or (3) filling agents such as lactose monohydrate, lactose anhydrous, microcrystalline cellulose and various starches; and or (4) lubricating agents such as agents that act on the flowability of the powder to be compressed, including colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, silica gel; and or (5) sweeteners such as any natural or artificial sweetener including sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame K; and or
(6) flavoring agents; and or
(7) preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic chemicals such as phenol, or quarternary compounds such as benzalkonium chloride; and or
(8) buffers; and or
(9) Diluents such as pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing; and or
(10) wetting agents such as corn starch, potato starch, maize starch, and modified starches, and mixtures thereof; and or
(11) disintegrants; such as croscarmellose sodium, crospovidone, sodium starch glycolate, and or
(12) effervescent agents such as effervescent couples such as an organic acid (e.g., citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts), or a carbonate (e.g. sodium carbonate, potassium carbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate) or bicarbonate (e.g. sodium bicarbonate or potassium bicarbonate); and or
(13) other pharmaceutically acceptable excipients.
Actual dosage levels of abiraterone acetate disclosure may be varied in accordance with the nature of the abiraterone acetate, as well as the potential increased efficacy due to the advantages of providing and administering the abiraterone acetate (e.g., increased solubility, more rapid dissolution, increased surface area of the abiraterone acetate, etc.). Thus as used herein "therapeutically effective amount" will refer to an amount of abiraterone acetate required to effect a therapeutic response in an animal. Amounts effective for such a use will depend on: the desired therapeutic effect; the route of administration; the potency of the abiraterone acetate; the desired duration of treatment; the stage and severity of the disease being treated; the weight and general state of health of the patient; and the judgment of the prescribing physician.
Pharmacokinetic Properties of Abiraterone acetate Compositions Fast Onset of Absorbtion In some embodiments, the abiraterone acetate compositions of the disclosure are rapidly absorbed. In one example, the abiraterone acetate compositions of the disclosure have a Tmax , when administered to an adult male in the fasted state, of less than about 2.5 hours (about 3 hours to about 2 hours), less than about 2.0 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, and more than about 1.0 hour, for example between 1.5 and 2.0 hrs Increased Bioavailability The abiraterone acetate compositions of the disclosure exhibit increased bioavailability (AUC) and require smaller doses as compared to prior conventional compositions administered at the same dose (e.g., Zytigag). In some cases an AUC and/or a Cmax similar to Zytiga0 can be achieved at lower dose than for Zytiga0. Thus, in some cases the pharmaceutical compositions described herein administered at a lower dose than Zytiga provide comparable systemic exposure. For example, a 500mg dose can be bioequivalent to a 1,000mg dose of Zytiga0.
Any drug composition can have adverse side effects. Thus, lower doses of drugs which can achieve the same or better therapeutic effect as those observed with larger doses of conventional compositions are desired. Such lower doses can be realized with the compositions of the disclosure because the greater bioavailability observed with the compositions as compared to conventional drug formulations means that smaller doses of drug are required to obtain the desired therapeutic effect.
The Pharmacokinetic Profiles of the Compositions of the Disclosure May be less Affected by the Fed or Fasted State of the Subject Ingesting the Compositions The disclosure encompasses abiraterone acetate compositions wherein the pharmacokinetic profile of the composition is less affected by the fed or fasted state of a subject ingesting the composition compared to Zytiga0. This means that there is a less difference in the quantity of composition or the rate of composition absorption when the compositions are administered in the fed versus the fasted state. Thus, in some cases the compositions of the disclosure reduce the effect of food on the pharmacokinetics of the composition compared to Zytiga0.
The Pharmacokinetic Profiles of the Compositions of the Disclosure May Exhibit Reduced Inter-patient Variability In some cases, the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUCO-00 may be less for an abiraterone acetate dosage form described herein than for Zytiga0.
Thus, the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUCO-Do can be 10%-50% less (at least 10% less, 10%-30% less, or 10%-20% less) than for Zytiga0.
(Calculated as CV (Zytiga0)-CV (present dosage form)/CV (Zytiga0) x 100%).
Pharmacokinetic Protocol Any standard pharmacokinetic protocol can be used to determine blood plasma concentration profile in humans following administration of a composition, and thereby establish whether that composition meets the pharmacokinetic criteria set out herein. For example, a randomized single-dose crossover study can be performed using a group of healthy adult human subjects.
The number of subjects should be sufficient to provide adequate control of variation in a statistical analysis, and is typically about 10 or greater, although for certain purposes a smaller group can suffice. Each subject receives by oral administration at time zero a single dose (e.g., 100 mg) of a test formulation of composition, normally at around 8 am following an overnight fast. The subjects continue to fast and remain in an upright position for about 4 hours after administration of the composition. Blood samples are collected from each subject prior to administration (e.g., 15 minutes) and at several intervals after administration. For the present purpose it is to take several samples within the first hour, and to sample less frequently thereafter. Illustratively, blood samples could be collected at 15, 30, 45, 60, and 90 minutes after administration, then every hour from 2 to 10 hours after administration.
Additional blood samples may also be taken later, for example at 12, 24, 36 and 48 hours after administration. If the same subjects are to be used for study of a second test formulation, a period of at least 7 days should elapse before administration of the second formulation. Plasma is separated from the blood samples by centrifugation and the separated plasma is analyzed for composition by a validated high performance liquid chromatography (HPLC) or liquid chromatography mass spectrometry (LCMS) procedure. Plasma concentrations of composition referenced herein are intended to mean total concentrations including both free and bound composition.
Modes of administration of medicaments comprising abiraterone acetates Medicaments of the disclosure can be administered to animals, including man, in any pharmaceutically acceptable manner, such as orally, rectally, pulmonary, intravaginally, locally (powders, ointments or drops), transdermal, parenteral administration, intravenous, intraperitoneal, intramuscular, sublingual or as a buccal or nasal spray.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, pellets, and granules. Further, incorporating any of the normally employed excipients, such as those previously listed, and generally 5-95% of the biologically active agent, and more preferably at a concentration of 10%-75% will form a pharmaceutically acceptable non-toxic oral composition.
However, if the abiraterone acetate is to be utilized in a liquid suspension, the particles comprising the abiraterone acetate may require further stabilization once the solid carrier has been substantially removed to ensure the elimination, or at least minimization of particle agglomeration.
Example 1. Preparation of Fine Particle Abiraterone Acetate Powder Blend Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the percentages shown in Table 1 to prepare a drug product intermediate for use in the preparation of tablets. Both lots of material were milled in a Union Process 1S attritor mill with a 0.5 gallon jacket-cooled tank. 200g batches were milled with milling bodies for 40 minutes.
Table 1: Drug Product Intermediate for Preparation of Tablets Ingredient Name and Formula 1 Formula 2 Grade (1/0w/w %w/w Abiraterone Acetate 20.00 30.00 Lactose Monohydrate, USP 78.50 67.75 Sodium Lauryl Sulfate, NF 1.50 2.25 Total 100.00 100.00 Example 2: Particle size analysis of milled and unmilled Abiraterone Acetate The particle size distribution of the abiraterone acetate in the two drug product intermediate lots described in Example 1 were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit.
Additionally, an unmilled blend of abiraterone acetate, lactose monohydrate and sodium lauryl sulfate was measured. All three samples were measured using the method as follows: the dispersant used was an aqueous solution of 0.1% povidone K30. Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube.
The tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off. The particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15% was reached and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds.
Three measurements were made and the average values of each particle size parameter were reported. Table 2 and Figure 1 show the particle size distributions; the data shows over a 10-fold reduction in particle size.
Table 2. Particle size Distribution of Unmilled and Milled Abiraterone Acetate Formula 1 Formula 2 Unmilled (20% AA) (30% AA) Dio 3.41 0.087 0.095 (micron) Dso 8.50 0.199 0.225 (micron) 16.4 0.463 0.538 (micron) 1)4,3 9.32 0.254 0.280 (micron) D3,2 6.46 0.164 0.183 (micron) Example 3: Preparation of Tablets and Comparative Dissolution Studies The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 3.
Table 3. Abiraterone Acetate 100 mg Tablet Composition Formula 1 Formula 2 Ingredient % w/w mg/tablet % w/w mg/tablet Abiraterone Acetate DPI
58.82 500.0 Formula 1 (20% AA) Abiraterone Acetate DPI
333.3 Formula 2 (30% AA) :]'! 47.62 Microcrystalline Cellulose, 33.38 283.7 44.53 311.7 NF Sodium Lauryl Sulfate, NF 0.3 2.6 0.35 2.5 Croscarmellose Sodium, NF 7 59.5 7 49.0 Sodium Stearyl Fumarate, NF 0.5 4.3 0.5 3.5 Total 100 850.0 100 700.0 The dissolution rates of the tablets prepared as described above were measured using the method listed on the FDA website for abiraterone acetate tablets, 250mg; USP
Apparatus II, 50 rpm in 900mL of pH 4.5 buffer with 0.25% sodium lauryl sulfate. Samples were analyzed by UV at 270nm. Additionally, for comparison purposes, Zytiga0 tablets were tested with the same dissolution conditions. The results of this analysis are shown in Table 4 and Figure 2. Full dissolution (>85% dissolved) was achieve in 10-20 minutes for the two tablet formulations contained milled abiraterone acetate, compared to Zytiga0 which had full dissolution (>85%
dissolved) in 60 minutes.
Table 4. Dissolution of Abiraterone Acetate Tablets Formula 1 (100mg Formula 2 (100 mg Zytiga0 (250mg abiraterone acetate) abiraterone acetate) abiraterone acetate) Avg % Std Avg % Std % Std Time[min] dissolved Deviation dissolved Deviation dissolved Deviation 50.9 14.3 63.8 12.4 16.3 1.8 81.9 10.9 87.4 6.4 30.2 2.8 88.3 2.9 92.4 4.8 52.6 3.3 93 9.1 93.7 4.8 80.2 9.7 60 95.5 7.1 94.9 4.4 95.5 1.2 Example 4: Abiraterone Acetate Tablets for Initial Phase I Study Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the amounts shown in Table 5 to prepare a drug product intermediate for use in the preparation of tablets for use in Phase I testing. The material was milled in a Union Process 1S
attritor mill with a 1.5 gallon jacket-cooled tank. The material was milled with milling bodies for 40 minutes.
Table 5: Drug Product Intermediate for Preparation of Tablets for Phase I
Testing Ingredient Name and Weight Quantity per Grade percent batch (g) Abiraterone Acetate 30.00 300.0 Lactose Monohydrate, USP 67.75 677.5 Sodium Lauryl Sulfate, NF 2.25 22.5 Total 100.00 1000.0 The particle size distribution of the abiraterone acetate in the milled drug product intermediate was measured with a Micromeritics Saturn DigiSizer II 5205 particle size analyzer configured with an AquaPrep II sample cell. The instrument sample reservoir was filled with dispersant solution (0.1% povidone K30). The sample was prepared by adding 100 mg of milled powder and 20 mL of dispersant to a 30 mL glass bottle. The particles were dispersed by agitation with a pipette, and then the capped bottle was placed in an ultrasonic water bath (Branson Ultrasonic bath, Model 5510-MT, output 135W, 42KHz) such that the bath water level was half way up the side of the bottle. The sample was then sonicated for 30 minutes. The dispersed sample was added dropwise to the reservoir of the liquid sample handling unit until an obscuration value of approximately 7% was reached. The internal sonic probe was run at 100%
intensity for 300 seconds, and then the sample was circulated for 120 seconds before data collection. Data were collected at a beam angle setting of 65 when the obscuration value was between 5 and 10%.
Each measurement was repeated in triplicate and the average of three measurements was reported. Particle size data from the milled powder are reported in Table 6.
Table 6: Milled Abiraterone Acetate Particle Size Particle Size Parameter Result (micron) Di 0.105 Dso 0.387 D90 1.308 D4,3 0.588 D3,2 0.247 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 7.
Table 7: Abiraterone Acetate 100 mg Tablet Composition for Initial Phase 1 Testing Ingredient % w/w mg/tablet Abiraterone Acetate 14.29 100.0 Lactose Monohydrate, NF 32.26 225.8 Sodium Lauryl Sulfate, NF 1.42 10.0 Microcrystalline Cellulose, NF 44.53 311.7 Croscarmellose Sodium, NF 7.00 49.0 Sodium Stearyl Fumarate, NF 0.50 3.5 Total 100.00 700.0 The dissolution rates of the tablets prepared as described above were measured in USP
Apparatus II, 75 rpm in 900mL of pH 4.5 buffer with 0.1% SLS. Samples were analyzed by HPLC. Additionally, for comparison purposes, Zytiga tablets were tested with the same dissolution conditions. Because Zytiga tablets are 250mg which is approaching the solubility limit of the dissolution media, the tablets were cut to a weight equivalent to 100mg of abiraterone acetate. Zytiga samples were measured using UV at 270nm. The results of this analysis are shown in Table 8; full dissolution (>85% dissolved) of the prepared tablets was achieved in 5 minutes, wheras the Zytiga tablets dissolution was achieved in 20 minutes.
Table 8: Dissolution of Abiraterone Acetate Tablets 100 mg 100mg Tablets for Phase 1 Zytiga tablets (cut to Clinical testing 100mg) Average (1/0 Average ')/0 Time (minutes) dissolved 'YoRSD dissolved (YoRSD
88 7.2 32.7 27.1 99 1.8 59.0 21.3 99 1.1 78.2 9.6 91.6 6.7 100 1.1 97.1 4.0 45 100 1.2 97.6 3.8 60 100 1.2 97.7 3.8 Example 5: Phase 1 Study of 100, 200, and 400 mg Doses of Abiraterone Acetate Formulation Compared to Zytiga 1000 mg The abiraterone acetate 100 mg tablet formulation prepared as described in Example 4 was tested in healthy male patients under fasting conditions at 100mg, 200mg, and 400mg doses (1, 2, or 4 x 100 mg tablets respectively). In the same study, a 1000mg dose of Zytiga was tested (4 x 250mg tablets). The results of this study are shown in Table 9.
Table 9: Abiraterone Acetate Tablets 100 mg Pharmacokinetic Data (Arithmetic Means) Milled Abiraterone Acetate w Zytiga R
i]]Pk Parameters Statistics 100 mg 200 mg 400 mg õõ 1,000 mg AUCo-in( (ng-hr/mL) Mean* 74.49 183.34 319.92 421.23 S.D. 42.22 86.7 140.74 183.83 CV (%) 56.68 47.29 43.99 43.64 Mean* 67.55 169.99 302.9 387.34 AUCot (ng=hr/mL) S.D. 39.37 83.73 137.17 168.67 CV (`)/0) 58.28 49.25 45.29 43.55 Mean* 17.28 39.11 65.42 79.46 C. (ng/mL) S.D. 10.41 21.69 35.58 39.56 CV (%) 60.29 55.46 54.39 49.78 Mean 1.55 1.78 2.32 2.16 imax (hour) S.D. 0.57 0.77 1.33 0.78 CV (%) 37.02 43.38 57.22 36.27 Mean* 4.72 7.83 8.84 14.48 t,A r) (h S.D. 2.57 3.88 2.96 5.11 CV (%) 54.35 49.51 33.45 35.32 K (h r-1 Mean 0.18 0.11 0.09 0.05 e ) S.D. 0.08 0.05 0.03 0.02 CV (%) 43.38 45.27 30.8 36.98 * Observed differences were highly significant (p<0.0001, ANOVA) among the four treatments.
A Observed differences were significant (p<0.05, Wilcoxon signed rank test), compared to Zytiga0 1,000 mg.
Example 6: Stability of Abiraterone Acetate Powder Blends and Tablets Total impurity growth of 0.2-0.6%AUC was detected by HPLC after abiraterone acetate was dry milled with lactose monohydrate and sodium lauryl sulfate. When the milled abiraterone acetate powder blend (or drug product intermediate; "DPI") was further processed into tablets, the level of impurities was found to be higher, about 0.5-1.1%. Stability testing showed that the impurities grew at 25 C/60%RH and at 40 C/75%RH, but did not grow at 2-8 C. In addition, impurity growth in the tablets was faster than that in the milled DPI. Table 10 and Figures 3A
and 3B (diamonds, 5 C; squares, 25 C/60% RH; and triangles, 40 C/75% RH) provide an overview of the impurity levels in lots of milled DPI and tablets upon accelerated stability testing. Tablets stored refrigerated had an acceptably low level of impurities, but it is desirable to have formulation that can be stored under ambient conditions.
Table 10. Abiraterone Acetate Stability (total impurities) Abiraterone Acetate DPI Abiraterone Acetate tablets, 100mg (contains milled API) (contains milled API) Time 25 C/60 % 40 C/75% 25 C/60% 40 C/75%
5oc 5oc (months) RH RH RH RH
0 0.20 0.44 0.44 0.73 0.48 0.48 1 0.33 0.65 0.65 0.77 0.78 3.02 2 0.34 0.65 1.21 0.77 1.86 3.34 3 0.28 0.8 1.71 0.72 2.25 4.49 The impurity growth in the DPI and tablets containing fine particle abiraterone acetate is due to oxidative degradation of abiraterone acetate. Aged Zytigag (abiraterone acetate) tablets were tested for purity, and the impurity levels were found to be much lower than aged tablets containing fine particle abiraterone acetate. The faster degradation in tablets containing fine particle abiraterone acetate could arise from a number of sources, including, but not limited to:
greater surface area of the API, higher proportion of excipient relative to the API, and differences in excipients. Further studies found that the API has some degradation in the presence of the excipients, but the degradation is greatly accelerated once the mixture is milled.
Data are provided in Table 11.
Table 11. Abiraterone Acetate Stability Total impurities Product Milling Stability by HPLC (%
AUC) Abiraterone Acetate (API) none 80 C, 4 hrs 0.23 SPEX shaker mill 80 C, 4 hrs 0.17 Drug Product Intermediate none 80 C, 4 hrs 0.28 (API, SLS, lactose monohydrate) SPEX shaker mill 80 C, 4 hrs 3.90 Tablet formulation (API, SLS, lactose monohydrate, none 80 C, 4 hrs 0.76 microcrystalline cellulose, croscarmellose sodium, sodium SPEX shaker mill 105 C, 4 hrs 10.00 stearyl fiimarate) Stored room Zytiga0 (abiraterone None temperature until 0.20 acetate) tablet expiry Example 7: Milling of Abiraterone with Antioxidant or Sequestering Agent Dry milling of abiraterone acetate was carried out in the presence of lactose monohydrate and sodium lauryl sulfate and various antioxidants and/or sequestering agents. In one study the dry milling included a combination of ascorbic acid and fumaric acid or a combination of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT): the formulations are shown in Table 12. Each lot was milled in a Union Process 1S attritor mill with a 0.5 gallon jacket-cooled tank. 200g batches were milled with milling bodies for 40 minutes. Both DPI
Formulas contained abiraterone acetate having a D90 below 1,000 nm, when tested per the light scattering method described in Example 2.
Table 12: DPI Formulation Containing Antioxidant or Sequestering Agent DPI Formulation DPI
Ascorbic/Fumari Formulation c BHA/BHT
Ingredient Function A w/w % w/w Abiraterone Acetate Active 30.00 30.00 Lactose Monohydrate Grinding compound 67.35 67.65 Sodium lauryl sulfate Facilitating agent 2.25 2.25 Ascorbic acid Antioxidant 0.20 ffiliMaiffiiMaiMM
Fumaric acid Sequestering agent 0.20 ¨
., õ ., ...õ..
Butylated Hydroxyanisole emoimimimimimin3 0.05 Antioxidant :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::i:::::::::
(BHA) .::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::::::::::::
Butylated Hydroxytoluene :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::::::::::::
Antioxidant .. 0.05 (BHT) TOTAL 100.00 100.00 The two different DPI Formulations were used to prepare two different corresponding tablet Formulation as detailed in Table 13 by adding the indicated excipients to the DPI Formulations, dry granulating and tableting.
Table 13: Tablet Formulations Containing Antioxidant or Sequestering Agent Tablet Tablet Formulation Formulation Ascorbic/Fumaric BHA/BHT
Function % w/w % w/w DPI Formulation Ascorbic/Fumaric (abiraterone acetate, lactose , ,=
47.62 mi s m monohydrate, SLS, ascorbic acid, :: ]i]] m fumaric acid) .:. , =
=
DPI Formulation BHA/BHT
(abiraterone acetate, lactose . 47.62 monohydrate, SLS, BHA, BHT) Microcrystalline cellulose Diluent 44.53 44.53 Sodium lauryl sulfate Wetting agent 0.35 0.35 Croscarmellose sodium Disintegrant 7.0 7.0 Sodium stearyl fumarate Lubricant 0.5 0.5 Total 100 100 The stability of the two tablet formulations was tested under accelerated conditions. Table 14 contains data demonstrating that both tablet formulations with antioxidant had dramatically improved stability after 3 months storage at 40 C/75%RH compared to the formulation without antioxidant, with the BHA/BHT formulation nearly halting all degradation. This demonstrates that the addition of antioxidants and/or sequestering agents during milling can dramatically improve stability.
Table 14. Tablet Stability data with and without Antioxidant Formulation Ascorbic Formulation No antioxidant Acid and Fumaric Acid BHA&BHT
Total Total Total Assay (% impurities Assay (% Impurities Assay (% Impurities condition label claim) (%AUC) label claim) (%AUC) label claim) (%AUC) Initial 98.6 0.48 101.5 0.31 101.6 0.16 1 month, 25 C/60%RH 98.1 0.78 100.9 0.89 101.1 0.15 1 month, 40 C/75%RH 92.4 3.02 96.8 1.13 100.7 0.19 2 month, 25 C/60%RH 97.5 1.86 95.5 1.26 96.7 0.13 2 month, 40 C/75%RH 92.8 3.36 97.5 1.46 97.4 0.16 3 months, 25 C/60%RH 95.2 2.25 97.8 1.75 95.5 0.45 3 months, 40 C/75%RH 92.5 4.49 96.0 1.90 98.6 0.70 The dissolution rate of the abiraterone acetate in the Tablet Formulation Ascorbic/Fumaric and Tablet Formulation BHA/BHT was tested using USP Apparatus II at 75 rpm in 900 ml of pH 4.5 phosphate buffer with 0.1% SLS. Tablets for all three types of tablets had full dissolution (>85% of the abiraterone acetate dissolved) within 10 minutes.
Example 8: Abiraterone Acetate Tablets for Additional Phase I Studies An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 15. The formulation was milled in a custom jacket-cooled 62 gallon attritor mill; the powder blend was milled with milling bodies for 72 minutes.
Table 15: Milled Drug Product Intermediate Containing BHA and BHT for Phase 1 clinical studies Quantity per batch Component Weight percent (g) Abiraterone Acetate 30.0 8.400 Lactose Monohydrate, USP 63.8 17.886 Sodium Lauryl Sulfate, NF 6.0 1.680 BHA 0.1 0.028 BHT 0.1 0.028 Total 100 28.000 The particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Two different methods were used to measure the particle size distributions, as described below:
Method 1: The dispersant used was an aqueous solution of 0.1% povidone K30.
Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube. The tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off. The particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15%
was reached and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
Method 2: The dispersant used was an aqueous solution comprising 0.1% of poloxamer 338 and 0.1% calcium chloride which was filtered through a 0.2 um nylon filter prior to use.
Approximately 20 mg of sample powder and 5 mL of dispersant solution was added to a glass vial. The vial was capped and swirled to disperse the powder particles. The vial cap was then loosened and the vial placed in the center of a sonic bath (Elma Elmsonic P3OH
ultrasonic bath).
The vial was immersed such that the bath liquid level was above the level of the dispersant in the vial, but the vial was not touching the bottom of the bath. The sample was sonicated at 37kHz at 100% power for ten minutes. The particle size analyzer sample dispersion unit was filled with dispersant and the sample was pipetted into the reservoir until an obscuration of 5-15% was obtained and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
Table 16 presents a comparison of the particle size values for abiraterone acetate in the drug product intermediate (DPI) described in Table 15 before and after milling, using Methods 1 and 2 described above.
Table 16: Particle Size Distribution Data for Abiraterone Acetate DPI
Containing BHA and BHT
Particle Size (}tm) Parameter Unmilled Milled Milled Method 1 Method 1 Method 2 Dio 1.64 0.153 0.124 Dso 3.07 0.747 0.286 D90 5.79 3.250 0.937 D4,3 3.44 1.300 0.479 D3,2 2.75 0.390 0.241 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 17.
Table 17: Milled Abiraterone Acetate Tablets 125 mg Composition Component % w/w mg/tablet Abiraterone Acetate 14.37 125.00 Lactose Monhydrate, NF 30.56 265.83 Sodium Lauryl Sulfate, NF 2.87 25.00 BHA (butylated hydroxyanisole), NF 0.05 0.42 BHT (butylated hydroxytoluene), NF 0.05 0.42 Microcrystalline Cellulose, NF 44.60 388.06 Croscarmellose Sodium, NF 7.00 60.90 Sodium Stearyl Fumarate, NF 0.50 4.38 Total 100.00 870.00 The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.12% SLS. Samples were analyzed by HPLC. The results of this analysis are shown in Table 18; full dissolution (>85% dissolved) was achieved in 10 minutes.
Table 18: Dissolution of Abiraterone Acetate Tablets Time % abiraterone (minutes) acetate dissolved "ZoRSD
53 6.6 86 3.4 93 3.5 30 95 2.9 45 95 3.1 60 95 3.0 Example 11: Phase I Study of 125, 500, and 625 mg Doses of Abiraterone Acetate Formulation Compared to Zytiga 1000 mg The abiraterone acetate 125mg tablet formulation prepared as described in Example 10 was tested in healthy male patients under fasting conditions at 125mg, 500mg, and 625mg doses (1, 4, or 5 x 125 mg tablets respectively). In the same study, a 1000mg dose of Zytiga0 was tested (4 x 250mg tablets). The results of this study are shown in Table 19.
Table 19: Abiraterone Acetate Tablets 125 mg Pharmacokinetic Data (Arithmetic Means) Milled Abiraterone Acetate Zytiga it rK Parametert !: Statistics :.m 0 125 mg: ,,,, 500 rrkg ::: 625 m,6,,. : : 1,000 mo Mean* 112.12 438.02 473.31 453.18 AUCo-ini. (ng=hr/mL) S.D. 65.94 249.43 247.19 219.07 CV (%) 58.81 56.94 52.23 48.34 Mean* 102.55 416.23 450.19 415.91 AUCot (ng-hr/mL) S.D. 63.27 245.73 241.85 210.67 CV (%) 61.7 59.04 53.72 50.65 Mean* 28.22 84.16 100.76 83.4 C. (ng/mL) S.D. 16.46 44.05 63.75 57.4 CV (%) 58.34 52.34 63.27 68.83 Mean 1.61 1.79 1.84 2.21 T. (hour) S.D. 0.98 1.12 0.97 1.44 CV (%) 61.16 62.55 52.61 65.34 r) Mean* 7.2 14.2 14.54 20.64 tv2(h S.D. 3.47 6.44 5.54 9.03 CV (%) 48.28 45.61 38.07 43.75 Ke (/hr) N 33 34 34 33 Mean 0.13 0.06 0.05 0.04 S.D. 0.09 0.05 0.02 0.02 CV (%) 65.7 71.26 36.1 46.69 Example 12: Additional Abiraterone Acetate Powder and Tablets An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 16. Two batches were milled with varying processing conditions, yielding slightly different particle size.
Table 16: Additional Milled Drug Product Intermediate Ingredient Weight percent Quantity per batch (g) Abiraterone Acetate 30.00 450.00 Lactose Monohydrate, USP 67.55 1013.25 Sodium Lauryl Sulfate, NF 2.25 33.75 Butylated Hydroxytoluene (BHT) 0.10 1.50 Butylated Hydroxyanisole (BHA) 0.10 1.50 total 100.00 1500.0 The particle size distribution of the abiraterone acetate in both lots of drug product intermediate were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 17.
Table 17: Additional Particle Size Distribution Data for Abiraterone Acetate DPI
Particle Size (ftm) Parameter Unmilled Batch 1, Milled Batch 2, Milled Di 1.69 1.17 1.36 Dso 3.55 2.13 2.46 D90 7.58 4.17 4.64 D4,3 5.94 5.45 4.46 D3,2 3.02 1.95 2.25 The milled drug product intermediate from Batch 1 was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 18.
Table 18: Milled Abiraterone Acetate Tablets 100 mg Composition Component A) w/w mg/tablet Abiraterone Acetate 14.29 100.0 Lactose Monhydrate, NF 32.17 10.0 Sodium Lauryl Sulfate, NF 1.42 0.3 BHA (butylated hydroxyanisole), NF 0.05 0.3 BHT (butylated hydroxytoluene), NF 0.05 225.2 Microcrystalline Cellulose, NF 44.53 311.7 Croscarmellose Sodium, NF 7.00 49.0 Sodium Stearyl Fumarate, NF 0.50 3.5 Total 100.0 700.0 The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.1% SLS. Samples were analyzed by UV at 270nm. The results of this analysis are shown in Table 19; full dissolution (>85% dissolved) was achieved in 10 minutes.
Table 19: Dissolution of Abiraterone Acetate Tablets, 100mg Time A abiraterone (minutes) acetate dissolved ')/oRSD
60.2 7.1 94.3 4.0 97.6 3.4 30 98.8 2.1 45 98.2 2.3 60 98.3 2.3 Example 13: Stability of Tablets An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 20.
Table 20: Milled Drug Product Intermediate Containing BHA and BHT
IngredientQuantity per batch Weight percent (kg) Abiraterone Acetate 30.00 7.44 Lactose Monohydrate, USP 63.8 15.82 Sodium Lauryl Sulfate, NF 6.0 1.49 Butylated Hydroxytoluene (BHT) 0.10 0.025 Butylated Hydroxyanisole (BHA) 0.10 0.025 total 100.00 24.80 The particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 21.
Table 21: Additional Particle Size Distribution Data for Abiraterone Acetate DPI Containing BHA and BHT
Particle Size (!lm) Parameter Unmilled Milled Di 1.69 0.184 D50 3.55 1.20 D90 7.58 3.57 D4,3 5.94 1.56 D3,2 3.02 0.49 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 22.
Table 22: Milled Abiraterone Acetate Tablets 125 mg Composition Ingredient % w/w mg/tablet Abiraterone acetate 14.34 125.00 Lactose monohydrate, USP 30.49 265.83 Butylated Hydroxytoluene (BHT) 0.05 0.42 Butylated Hydroxyanisole (BHA) 0.05 0.42 sodium lauryl sulfate, NF 2.87 25.00 Microcrystalline cellulose, NF 44.69 389.63 Croscarmellose sodium ,NF 7.02 61.25 Sodium stearyl fumarate,NF 0.50 4.38 total 100.00 871.92 Tablets were packaged and mounted on accelerated stability at 40 C and 75%
relative humidity.
Impurities were measured by a stability-indicating HPLC method. The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.12%
SLS. The results are shown in Table 23; no impurity growth was observed over 3 months at 40 C/75%RH, and the dissolution remained unchanged with full dissolution (>85% dissolved) within 10 minutes over 3 months at 40 C/75%RH.
Table 23. Stability of Abiraterone Acetate Tablets, 125mg Abiraterone Acetate Tablets, 125mg 1 month 2 month 3 month Initial 40 C/75%RH 40 C/75%RH 40 C/75%RH
Total Impurities (%AUC) 0.05 <0.05 0.05 <0.05 Avg % Avg % Avg %
Time dissolv Avg % dissolve dissolved (minutes ed %RS dissolve %R d (n=3) %RS (n=3) ) (n=6) D d (n=3) SD D %RSD
4 60.8 10.2 60.3 8.3 63.4 8.0 65.3 8.6 6 81.3 8.3 80.0 5.0 87.2 3.0 85.8 2.9 8 92.1 1.5 91.6 4.2 94.2 1.2 93.8 0.7 93.9 1.2 93.6 2.9 95.5 0.8 95.3 0.6 95.0 1.4 97.4 1.9 97.4 0.6 97.4 0.4 95.3 1.4 97.7 0.6 98.0 0.3 97.3 0.8 95.4 1.9 98.0 0.1 99.3 2.9 97.0 1.2 60 98.1 4.7 97.4 0.7 99.0 1.2 97.2 0.7 Example 14: Effect of Fed or Fasted State The effect of a high fat meal on the oral bioavailability of a 500mg dose of 125mg milled abiraterone mg tablets was evaluated in a single-center, single-dose, randomized, open-label, 2-period, 2-treatment crossover pharmacokinetic study. During the first dosing period, approximately half of the subjects were administered the test article with 240 mL of water, after a 10 hour fast. The remaining subjects were given the test article approximately 30 minutes after consuming a standard FDA high fat breakfast. After a seven day washout period, each subject was crossed over to the other treatment. Plasma samples were taken immediately prior to dosing and at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0, and 48.0 hours after administration of the test article. Samples were analyzed for abiraterone concentration, and the results were used to calculate pharmacokinetic parameters (AUCo-., AUCo-t, and Cmax) for each subject and treatment. The geometric mean values for AUCo-o,, AUCo-t, and Cmax when the test article was administered in the fed state were 1444.1 ng-h/mL, 1393.4 ng-h/mL, and 443.7 ng/mL respectively, while the geometric mean values for those same parameters were 322.7 ng=h/mL, 301.0 ng=h/mL, and 67.9 ng/mL when the drug was administered in the fasted state.
The ratios (fed/fasted) for AUCo-., AUCo-t, and C. were 4.48, 4.63, and 6.53, respectively.
Actual dosage levels of abiraterone acetate disclosure may be varied in accordance with the nature of the abiraterone acetate, as well as the potential increased efficacy due to the advantages of providing and administering the abiraterone acetate (e.g., increased solubility, more rapid dissolution, increased surface area of the abiraterone acetate, etc.). Thus as used herein "therapeutically effective amount" will refer to an amount of abiraterone acetate required to effect a therapeutic response in an animal. Amounts effective for such a use will depend on: the desired therapeutic effect; the route of administration; the potency of the abiraterone acetate; the desired duration of treatment; the stage and severity of the disease being treated; the weight and general state of health of the patient; and the judgment of the prescribing physician.
Pharmacokinetic Properties of Abiraterone acetate Compositions Fast Onset of Absorbtion In some embodiments, the abiraterone acetate compositions of the disclosure are rapidly absorbed. In one example, the abiraterone acetate compositions of the disclosure have a Tmax , when administered to an adult male in the fasted state, of less than about 2.5 hours (about 3 hours to about 2 hours), less than about 2.0 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, and more than about 1.0 hour, for example between 1.5 and 2.0 hrs Increased Bioavailability The abiraterone acetate compositions of the disclosure exhibit increased bioavailability (AUC) and require smaller doses as compared to prior conventional compositions administered at the same dose (e.g., Zytigag). In some cases an AUC and/or a Cmax similar to Zytiga0 can be achieved at lower dose than for Zytiga0. Thus, in some cases the pharmaceutical compositions described herein administered at a lower dose than Zytiga provide comparable systemic exposure. For example, a 500mg dose can be bioequivalent to a 1,000mg dose of Zytiga0.
Any drug composition can have adverse side effects. Thus, lower doses of drugs which can achieve the same or better therapeutic effect as those observed with larger doses of conventional compositions are desired. Such lower doses can be realized with the compositions of the disclosure because the greater bioavailability observed with the compositions as compared to conventional drug formulations means that smaller doses of drug are required to obtain the desired therapeutic effect.
The Pharmacokinetic Profiles of the Compositions of the Disclosure May be less Affected by the Fed or Fasted State of the Subject Ingesting the Compositions The disclosure encompasses abiraterone acetate compositions wherein the pharmacokinetic profile of the composition is less affected by the fed or fasted state of a subject ingesting the composition compared to Zytiga0. This means that there is a less difference in the quantity of composition or the rate of composition absorption when the compositions are administered in the fed versus the fasted state. Thus, in some cases the compositions of the disclosure reduce the effect of food on the pharmacokinetics of the composition compared to Zytiga0.
The Pharmacokinetic Profiles of the Compositions of the Disclosure May Exhibit Reduced Inter-patient Variability In some cases, the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUCO-00 may be less for an abiraterone acetate dosage form described herein than for Zytiga0.
Thus, the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUCO-Do can be 10%-50% less (at least 10% less, 10%-30% less, or 10%-20% less) than for Zytiga0.
(Calculated as CV (Zytiga0)-CV (present dosage form)/CV (Zytiga0) x 100%).
Pharmacokinetic Protocol Any standard pharmacokinetic protocol can be used to determine blood plasma concentration profile in humans following administration of a composition, and thereby establish whether that composition meets the pharmacokinetic criteria set out herein. For example, a randomized single-dose crossover study can be performed using a group of healthy adult human subjects.
The number of subjects should be sufficient to provide adequate control of variation in a statistical analysis, and is typically about 10 or greater, although for certain purposes a smaller group can suffice. Each subject receives by oral administration at time zero a single dose (e.g., 100 mg) of a test formulation of composition, normally at around 8 am following an overnight fast. The subjects continue to fast and remain in an upright position for about 4 hours after administration of the composition. Blood samples are collected from each subject prior to administration (e.g., 15 minutes) and at several intervals after administration. For the present purpose it is to take several samples within the first hour, and to sample less frequently thereafter. Illustratively, blood samples could be collected at 15, 30, 45, 60, and 90 minutes after administration, then every hour from 2 to 10 hours after administration.
Additional blood samples may also be taken later, for example at 12, 24, 36 and 48 hours after administration. If the same subjects are to be used for study of a second test formulation, a period of at least 7 days should elapse before administration of the second formulation. Plasma is separated from the blood samples by centrifugation and the separated plasma is analyzed for composition by a validated high performance liquid chromatography (HPLC) or liquid chromatography mass spectrometry (LCMS) procedure. Plasma concentrations of composition referenced herein are intended to mean total concentrations including both free and bound composition.
Modes of administration of medicaments comprising abiraterone acetates Medicaments of the disclosure can be administered to animals, including man, in any pharmaceutically acceptable manner, such as orally, rectally, pulmonary, intravaginally, locally (powders, ointments or drops), transdermal, parenteral administration, intravenous, intraperitoneal, intramuscular, sublingual or as a buccal or nasal spray.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, pellets, and granules. Further, incorporating any of the normally employed excipients, such as those previously listed, and generally 5-95% of the biologically active agent, and more preferably at a concentration of 10%-75% will form a pharmaceutically acceptable non-toxic oral composition.
However, if the abiraterone acetate is to be utilized in a liquid suspension, the particles comprising the abiraterone acetate may require further stabilization once the solid carrier has been substantially removed to ensure the elimination, or at least minimization of particle agglomeration.
Example 1. Preparation of Fine Particle Abiraterone Acetate Powder Blend Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the percentages shown in Table 1 to prepare a drug product intermediate for use in the preparation of tablets. Both lots of material were milled in a Union Process 1S attritor mill with a 0.5 gallon jacket-cooled tank. 200g batches were milled with milling bodies for 40 minutes.
Table 1: Drug Product Intermediate for Preparation of Tablets Ingredient Name and Formula 1 Formula 2 Grade (1/0w/w %w/w Abiraterone Acetate 20.00 30.00 Lactose Monohydrate, USP 78.50 67.75 Sodium Lauryl Sulfate, NF 1.50 2.25 Total 100.00 100.00 Example 2: Particle size analysis of milled and unmilled Abiraterone Acetate The particle size distribution of the abiraterone acetate in the two drug product intermediate lots described in Example 1 were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit.
Additionally, an unmilled blend of abiraterone acetate, lactose monohydrate and sodium lauryl sulfate was measured. All three samples were measured using the method as follows: the dispersant used was an aqueous solution of 0.1% povidone K30. Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube.
The tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off. The particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15% was reached and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds.
Three measurements were made and the average values of each particle size parameter were reported. Table 2 and Figure 1 show the particle size distributions; the data shows over a 10-fold reduction in particle size.
Table 2. Particle size Distribution of Unmilled and Milled Abiraterone Acetate Formula 1 Formula 2 Unmilled (20% AA) (30% AA) Dio 3.41 0.087 0.095 (micron) Dso 8.50 0.199 0.225 (micron) 16.4 0.463 0.538 (micron) 1)4,3 9.32 0.254 0.280 (micron) D3,2 6.46 0.164 0.183 (micron) Example 3: Preparation of Tablets and Comparative Dissolution Studies The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 3.
Table 3. Abiraterone Acetate 100 mg Tablet Composition Formula 1 Formula 2 Ingredient % w/w mg/tablet % w/w mg/tablet Abiraterone Acetate DPI
58.82 500.0 Formula 1 (20% AA) Abiraterone Acetate DPI
333.3 Formula 2 (30% AA) :]'! 47.62 Microcrystalline Cellulose, 33.38 283.7 44.53 311.7 NF Sodium Lauryl Sulfate, NF 0.3 2.6 0.35 2.5 Croscarmellose Sodium, NF 7 59.5 7 49.0 Sodium Stearyl Fumarate, NF 0.5 4.3 0.5 3.5 Total 100 850.0 100 700.0 The dissolution rates of the tablets prepared as described above were measured using the method listed on the FDA website for abiraterone acetate tablets, 250mg; USP
Apparatus II, 50 rpm in 900mL of pH 4.5 buffer with 0.25% sodium lauryl sulfate. Samples were analyzed by UV at 270nm. Additionally, for comparison purposes, Zytiga0 tablets were tested with the same dissolution conditions. The results of this analysis are shown in Table 4 and Figure 2. Full dissolution (>85% dissolved) was achieve in 10-20 minutes for the two tablet formulations contained milled abiraterone acetate, compared to Zytiga0 which had full dissolution (>85%
dissolved) in 60 minutes.
Table 4. Dissolution of Abiraterone Acetate Tablets Formula 1 (100mg Formula 2 (100 mg Zytiga0 (250mg abiraterone acetate) abiraterone acetate) abiraterone acetate) Avg % Std Avg % Std % Std Time[min] dissolved Deviation dissolved Deviation dissolved Deviation 50.9 14.3 63.8 12.4 16.3 1.8 81.9 10.9 87.4 6.4 30.2 2.8 88.3 2.9 92.4 4.8 52.6 3.3 93 9.1 93.7 4.8 80.2 9.7 60 95.5 7.1 94.9 4.4 95.5 1.2 Example 4: Abiraterone Acetate Tablets for Initial Phase I Study Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the amounts shown in Table 5 to prepare a drug product intermediate for use in the preparation of tablets for use in Phase I testing. The material was milled in a Union Process 1S
attritor mill with a 1.5 gallon jacket-cooled tank. The material was milled with milling bodies for 40 minutes.
Table 5: Drug Product Intermediate for Preparation of Tablets for Phase I
Testing Ingredient Name and Weight Quantity per Grade percent batch (g) Abiraterone Acetate 30.00 300.0 Lactose Monohydrate, USP 67.75 677.5 Sodium Lauryl Sulfate, NF 2.25 22.5 Total 100.00 1000.0 The particle size distribution of the abiraterone acetate in the milled drug product intermediate was measured with a Micromeritics Saturn DigiSizer II 5205 particle size analyzer configured with an AquaPrep II sample cell. The instrument sample reservoir was filled with dispersant solution (0.1% povidone K30). The sample was prepared by adding 100 mg of milled powder and 20 mL of dispersant to a 30 mL glass bottle. The particles were dispersed by agitation with a pipette, and then the capped bottle was placed in an ultrasonic water bath (Branson Ultrasonic bath, Model 5510-MT, output 135W, 42KHz) such that the bath water level was half way up the side of the bottle. The sample was then sonicated for 30 minutes. The dispersed sample was added dropwise to the reservoir of the liquid sample handling unit until an obscuration value of approximately 7% was reached. The internal sonic probe was run at 100%
intensity for 300 seconds, and then the sample was circulated for 120 seconds before data collection. Data were collected at a beam angle setting of 65 when the obscuration value was between 5 and 10%.
Each measurement was repeated in triplicate and the average of three measurements was reported. Particle size data from the milled powder are reported in Table 6.
Table 6: Milled Abiraterone Acetate Particle Size Particle Size Parameter Result (micron) Di 0.105 Dso 0.387 D90 1.308 D4,3 0.588 D3,2 0.247 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 7.
Table 7: Abiraterone Acetate 100 mg Tablet Composition for Initial Phase 1 Testing Ingredient % w/w mg/tablet Abiraterone Acetate 14.29 100.0 Lactose Monohydrate, NF 32.26 225.8 Sodium Lauryl Sulfate, NF 1.42 10.0 Microcrystalline Cellulose, NF 44.53 311.7 Croscarmellose Sodium, NF 7.00 49.0 Sodium Stearyl Fumarate, NF 0.50 3.5 Total 100.00 700.0 The dissolution rates of the tablets prepared as described above were measured in USP
Apparatus II, 75 rpm in 900mL of pH 4.5 buffer with 0.1% SLS. Samples were analyzed by HPLC. Additionally, for comparison purposes, Zytiga tablets were tested with the same dissolution conditions. Because Zytiga tablets are 250mg which is approaching the solubility limit of the dissolution media, the tablets were cut to a weight equivalent to 100mg of abiraterone acetate. Zytiga samples were measured using UV at 270nm. The results of this analysis are shown in Table 8; full dissolution (>85% dissolved) of the prepared tablets was achieved in 5 minutes, wheras the Zytiga tablets dissolution was achieved in 20 minutes.
Table 8: Dissolution of Abiraterone Acetate Tablets 100 mg 100mg Tablets for Phase 1 Zytiga tablets (cut to Clinical testing 100mg) Average (1/0 Average ')/0 Time (minutes) dissolved 'YoRSD dissolved (YoRSD
88 7.2 32.7 27.1 99 1.8 59.0 21.3 99 1.1 78.2 9.6 91.6 6.7 100 1.1 97.1 4.0 45 100 1.2 97.6 3.8 60 100 1.2 97.7 3.8 Example 5: Phase 1 Study of 100, 200, and 400 mg Doses of Abiraterone Acetate Formulation Compared to Zytiga 1000 mg The abiraterone acetate 100 mg tablet formulation prepared as described in Example 4 was tested in healthy male patients under fasting conditions at 100mg, 200mg, and 400mg doses (1, 2, or 4 x 100 mg tablets respectively). In the same study, a 1000mg dose of Zytiga was tested (4 x 250mg tablets). The results of this study are shown in Table 9.
Table 9: Abiraterone Acetate Tablets 100 mg Pharmacokinetic Data (Arithmetic Means) Milled Abiraterone Acetate w Zytiga R
i]]Pk Parameters Statistics 100 mg 200 mg 400 mg õõ 1,000 mg AUCo-in( (ng-hr/mL) Mean* 74.49 183.34 319.92 421.23 S.D. 42.22 86.7 140.74 183.83 CV (%) 56.68 47.29 43.99 43.64 Mean* 67.55 169.99 302.9 387.34 AUCot (ng=hr/mL) S.D. 39.37 83.73 137.17 168.67 CV (`)/0) 58.28 49.25 45.29 43.55 Mean* 17.28 39.11 65.42 79.46 C. (ng/mL) S.D. 10.41 21.69 35.58 39.56 CV (%) 60.29 55.46 54.39 49.78 Mean 1.55 1.78 2.32 2.16 imax (hour) S.D. 0.57 0.77 1.33 0.78 CV (%) 37.02 43.38 57.22 36.27 Mean* 4.72 7.83 8.84 14.48 t,A r) (h S.D. 2.57 3.88 2.96 5.11 CV (%) 54.35 49.51 33.45 35.32 K (h r-1 Mean 0.18 0.11 0.09 0.05 e ) S.D. 0.08 0.05 0.03 0.02 CV (%) 43.38 45.27 30.8 36.98 * Observed differences were highly significant (p<0.0001, ANOVA) among the four treatments.
A Observed differences were significant (p<0.05, Wilcoxon signed rank test), compared to Zytiga0 1,000 mg.
Example 6: Stability of Abiraterone Acetate Powder Blends and Tablets Total impurity growth of 0.2-0.6%AUC was detected by HPLC after abiraterone acetate was dry milled with lactose monohydrate and sodium lauryl sulfate. When the milled abiraterone acetate powder blend (or drug product intermediate; "DPI") was further processed into tablets, the level of impurities was found to be higher, about 0.5-1.1%. Stability testing showed that the impurities grew at 25 C/60%RH and at 40 C/75%RH, but did not grow at 2-8 C. In addition, impurity growth in the tablets was faster than that in the milled DPI. Table 10 and Figures 3A
and 3B (diamonds, 5 C; squares, 25 C/60% RH; and triangles, 40 C/75% RH) provide an overview of the impurity levels in lots of milled DPI and tablets upon accelerated stability testing. Tablets stored refrigerated had an acceptably low level of impurities, but it is desirable to have formulation that can be stored under ambient conditions.
Table 10. Abiraterone Acetate Stability (total impurities) Abiraterone Acetate DPI Abiraterone Acetate tablets, 100mg (contains milled API) (contains milled API) Time 25 C/60 % 40 C/75% 25 C/60% 40 C/75%
5oc 5oc (months) RH RH RH RH
0 0.20 0.44 0.44 0.73 0.48 0.48 1 0.33 0.65 0.65 0.77 0.78 3.02 2 0.34 0.65 1.21 0.77 1.86 3.34 3 0.28 0.8 1.71 0.72 2.25 4.49 The impurity growth in the DPI and tablets containing fine particle abiraterone acetate is due to oxidative degradation of abiraterone acetate. Aged Zytigag (abiraterone acetate) tablets were tested for purity, and the impurity levels were found to be much lower than aged tablets containing fine particle abiraterone acetate. The faster degradation in tablets containing fine particle abiraterone acetate could arise from a number of sources, including, but not limited to:
greater surface area of the API, higher proportion of excipient relative to the API, and differences in excipients. Further studies found that the API has some degradation in the presence of the excipients, but the degradation is greatly accelerated once the mixture is milled.
Data are provided in Table 11.
Table 11. Abiraterone Acetate Stability Total impurities Product Milling Stability by HPLC (%
AUC) Abiraterone Acetate (API) none 80 C, 4 hrs 0.23 SPEX shaker mill 80 C, 4 hrs 0.17 Drug Product Intermediate none 80 C, 4 hrs 0.28 (API, SLS, lactose monohydrate) SPEX shaker mill 80 C, 4 hrs 3.90 Tablet formulation (API, SLS, lactose monohydrate, none 80 C, 4 hrs 0.76 microcrystalline cellulose, croscarmellose sodium, sodium SPEX shaker mill 105 C, 4 hrs 10.00 stearyl fiimarate) Stored room Zytiga0 (abiraterone None temperature until 0.20 acetate) tablet expiry Example 7: Milling of Abiraterone with Antioxidant or Sequestering Agent Dry milling of abiraterone acetate was carried out in the presence of lactose monohydrate and sodium lauryl sulfate and various antioxidants and/or sequestering agents. In one study the dry milling included a combination of ascorbic acid and fumaric acid or a combination of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT): the formulations are shown in Table 12. Each lot was milled in a Union Process 1S attritor mill with a 0.5 gallon jacket-cooled tank. 200g batches were milled with milling bodies for 40 minutes. Both DPI
Formulas contained abiraterone acetate having a D90 below 1,000 nm, when tested per the light scattering method described in Example 2.
Table 12: DPI Formulation Containing Antioxidant or Sequestering Agent DPI Formulation DPI
Ascorbic/Fumari Formulation c BHA/BHT
Ingredient Function A w/w % w/w Abiraterone Acetate Active 30.00 30.00 Lactose Monohydrate Grinding compound 67.35 67.65 Sodium lauryl sulfate Facilitating agent 2.25 2.25 Ascorbic acid Antioxidant 0.20 ffiliMaiffiiMaiMM
Fumaric acid Sequestering agent 0.20 ¨
., õ ., ...õ..
Butylated Hydroxyanisole emoimimimimimin3 0.05 Antioxidant :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::i:::::::::
(BHA) .::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::::::::::::
Butylated Hydroxytoluene :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
::::::::::::
Antioxidant .. 0.05 (BHT) TOTAL 100.00 100.00 The two different DPI Formulations were used to prepare two different corresponding tablet Formulation as detailed in Table 13 by adding the indicated excipients to the DPI Formulations, dry granulating and tableting.
Table 13: Tablet Formulations Containing Antioxidant or Sequestering Agent Tablet Tablet Formulation Formulation Ascorbic/Fumaric BHA/BHT
Function % w/w % w/w DPI Formulation Ascorbic/Fumaric (abiraterone acetate, lactose , ,=
47.62 mi s m monohydrate, SLS, ascorbic acid, :: ]i]] m fumaric acid) .:. , =
=
DPI Formulation BHA/BHT
(abiraterone acetate, lactose . 47.62 monohydrate, SLS, BHA, BHT) Microcrystalline cellulose Diluent 44.53 44.53 Sodium lauryl sulfate Wetting agent 0.35 0.35 Croscarmellose sodium Disintegrant 7.0 7.0 Sodium stearyl fumarate Lubricant 0.5 0.5 Total 100 100 The stability of the two tablet formulations was tested under accelerated conditions. Table 14 contains data demonstrating that both tablet formulations with antioxidant had dramatically improved stability after 3 months storage at 40 C/75%RH compared to the formulation without antioxidant, with the BHA/BHT formulation nearly halting all degradation. This demonstrates that the addition of antioxidants and/or sequestering agents during milling can dramatically improve stability.
Table 14. Tablet Stability data with and without Antioxidant Formulation Ascorbic Formulation No antioxidant Acid and Fumaric Acid BHA&BHT
Total Total Total Assay (% impurities Assay (% Impurities Assay (% Impurities condition label claim) (%AUC) label claim) (%AUC) label claim) (%AUC) Initial 98.6 0.48 101.5 0.31 101.6 0.16 1 month, 25 C/60%RH 98.1 0.78 100.9 0.89 101.1 0.15 1 month, 40 C/75%RH 92.4 3.02 96.8 1.13 100.7 0.19 2 month, 25 C/60%RH 97.5 1.86 95.5 1.26 96.7 0.13 2 month, 40 C/75%RH 92.8 3.36 97.5 1.46 97.4 0.16 3 months, 25 C/60%RH 95.2 2.25 97.8 1.75 95.5 0.45 3 months, 40 C/75%RH 92.5 4.49 96.0 1.90 98.6 0.70 The dissolution rate of the abiraterone acetate in the Tablet Formulation Ascorbic/Fumaric and Tablet Formulation BHA/BHT was tested using USP Apparatus II at 75 rpm in 900 ml of pH 4.5 phosphate buffer with 0.1% SLS. Tablets for all three types of tablets had full dissolution (>85% of the abiraterone acetate dissolved) within 10 minutes.
Example 8: Abiraterone Acetate Tablets for Additional Phase I Studies An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 15. The formulation was milled in a custom jacket-cooled 62 gallon attritor mill; the powder blend was milled with milling bodies for 72 minutes.
Table 15: Milled Drug Product Intermediate Containing BHA and BHT for Phase 1 clinical studies Quantity per batch Component Weight percent (g) Abiraterone Acetate 30.0 8.400 Lactose Monohydrate, USP 63.8 17.886 Sodium Lauryl Sulfate, NF 6.0 1.680 BHA 0.1 0.028 BHT 0.1 0.028 Total 100 28.000 The particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Two different methods were used to measure the particle size distributions, as described below:
Method 1: The dispersant used was an aqueous solution of 0.1% povidone K30.
Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube. The tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off. The particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15%
was reached and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
Method 2: The dispersant used was an aqueous solution comprising 0.1% of poloxamer 338 and 0.1% calcium chloride which was filtered through a 0.2 um nylon filter prior to use.
Approximately 20 mg of sample powder and 5 mL of dispersant solution was added to a glass vial. The vial was capped and swirled to disperse the powder particles. The vial cap was then loosened and the vial placed in the center of a sonic bath (Elma Elmsonic P3OH
ultrasonic bath).
The vial was immersed such that the bath liquid level was above the level of the dispersant in the vial, but the vial was not touching the bottom of the bath. The sample was sonicated at 37kHz at 100% power for ten minutes. The particle size analyzer sample dispersion unit was filled with dispersant and the sample was pipetted into the reservoir until an obscuration of 5-15% was obtained and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
Table 16 presents a comparison of the particle size values for abiraterone acetate in the drug product intermediate (DPI) described in Table 15 before and after milling, using Methods 1 and 2 described above.
Table 16: Particle Size Distribution Data for Abiraterone Acetate DPI
Containing BHA and BHT
Particle Size (}tm) Parameter Unmilled Milled Milled Method 1 Method 1 Method 2 Dio 1.64 0.153 0.124 Dso 3.07 0.747 0.286 D90 5.79 3.250 0.937 D4,3 3.44 1.300 0.479 D3,2 2.75 0.390 0.241 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 17.
Table 17: Milled Abiraterone Acetate Tablets 125 mg Composition Component % w/w mg/tablet Abiraterone Acetate 14.37 125.00 Lactose Monhydrate, NF 30.56 265.83 Sodium Lauryl Sulfate, NF 2.87 25.00 BHA (butylated hydroxyanisole), NF 0.05 0.42 BHT (butylated hydroxytoluene), NF 0.05 0.42 Microcrystalline Cellulose, NF 44.60 388.06 Croscarmellose Sodium, NF 7.00 60.90 Sodium Stearyl Fumarate, NF 0.50 4.38 Total 100.00 870.00 The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.12% SLS. Samples were analyzed by HPLC. The results of this analysis are shown in Table 18; full dissolution (>85% dissolved) was achieved in 10 minutes.
Table 18: Dissolution of Abiraterone Acetate Tablets Time % abiraterone (minutes) acetate dissolved "ZoRSD
53 6.6 86 3.4 93 3.5 30 95 2.9 45 95 3.1 60 95 3.0 Example 11: Phase I Study of 125, 500, and 625 mg Doses of Abiraterone Acetate Formulation Compared to Zytiga 1000 mg The abiraterone acetate 125mg tablet formulation prepared as described in Example 10 was tested in healthy male patients under fasting conditions at 125mg, 500mg, and 625mg doses (1, 4, or 5 x 125 mg tablets respectively). In the same study, a 1000mg dose of Zytiga0 was tested (4 x 250mg tablets). The results of this study are shown in Table 19.
Table 19: Abiraterone Acetate Tablets 125 mg Pharmacokinetic Data (Arithmetic Means) Milled Abiraterone Acetate Zytiga it rK Parametert !: Statistics :.m 0 125 mg: ,,,, 500 rrkg ::: 625 m,6,,. : : 1,000 mo Mean* 112.12 438.02 473.31 453.18 AUCo-ini. (ng=hr/mL) S.D. 65.94 249.43 247.19 219.07 CV (%) 58.81 56.94 52.23 48.34 Mean* 102.55 416.23 450.19 415.91 AUCot (ng-hr/mL) S.D. 63.27 245.73 241.85 210.67 CV (%) 61.7 59.04 53.72 50.65 Mean* 28.22 84.16 100.76 83.4 C. (ng/mL) S.D. 16.46 44.05 63.75 57.4 CV (%) 58.34 52.34 63.27 68.83 Mean 1.61 1.79 1.84 2.21 T. (hour) S.D. 0.98 1.12 0.97 1.44 CV (%) 61.16 62.55 52.61 65.34 r) Mean* 7.2 14.2 14.54 20.64 tv2(h S.D. 3.47 6.44 5.54 9.03 CV (%) 48.28 45.61 38.07 43.75 Ke (/hr) N 33 34 34 33 Mean 0.13 0.06 0.05 0.04 S.D. 0.09 0.05 0.02 0.02 CV (%) 65.7 71.26 36.1 46.69 Example 12: Additional Abiraterone Acetate Powder and Tablets An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 16. Two batches were milled with varying processing conditions, yielding slightly different particle size.
Table 16: Additional Milled Drug Product Intermediate Ingredient Weight percent Quantity per batch (g) Abiraterone Acetate 30.00 450.00 Lactose Monohydrate, USP 67.55 1013.25 Sodium Lauryl Sulfate, NF 2.25 33.75 Butylated Hydroxytoluene (BHT) 0.10 1.50 Butylated Hydroxyanisole (BHA) 0.10 1.50 total 100.00 1500.0 The particle size distribution of the abiraterone acetate in both lots of drug product intermediate were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 17.
Table 17: Additional Particle Size Distribution Data for Abiraterone Acetate DPI
Particle Size (ftm) Parameter Unmilled Batch 1, Milled Batch 2, Milled Di 1.69 1.17 1.36 Dso 3.55 2.13 2.46 D90 7.58 4.17 4.64 D4,3 5.94 5.45 4.46 D3,2 3.02 1.95 2.25 The milled drug product intermediate from Batch 1 was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 100mg abiraterone acetate tablets having the composition shown in Table 18.
Table 18: Milled Abiraterone Acetate Tablets 100 mg Composition Component A) w/w mg/tablet Abiraterone Acetate 14.29 100.0 Lactose Monhydrate, NF 32.17 10.0 Sodium Lauryl Sulfate, NF 1.42 0.3 BHA (butylated hydroxyanisole), NF 0.05 0.3 BHT (butylated hydroxytoluene), NF 0.05 225.2 Microcrystalline Cellulose, NF 44.53 311.7 Croscarmellose Sodium, NF 7.00 49.0 Sodium Stearyl Fumarate, NF 0.50 3.5 Total 100.0 700.0 The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.1% SLS. Samples were analyzed by UV at 270nm. The results of this analysis are shown in Table 19; full dissolution (>85% dissolved) was achieved in 10 minutes.
Table 19: Dissolution of Abiraterone Acetate Tablets, 100mg Time A abiraterone (minutes) acetate dissolved ')/oRSD
60.2 7.1 94.3 4.0 97.6 3.4 30 98.8 2.1 45 98.2 2.3 60 98.3 2.3 Example 13: Stability of Tablets An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 20.
Table 20: Milled Drug Product Intermediate Containing BHA and BHT
IngredientQuantity per batch Weight percent (kg) Abiraterone Acetate 30.00 7.44 Lactose Monohydrate, USP 63.8 15.82 Sodium Lauryl Sulfate, NF 6.0 1.49 Butylated Hydroxytoluene (BHT) 0.10 0.025 Butylated Hydroxyanisole (BHA) 0.10 0.025 total 100.00 24.80 The particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 21.
Table 21: Additional Particle Size Distribution Data for Abiraterone Acetate DPI Containing BHA and BHT
Particle Size (!lm) Parameter Unmilled Milled Di 1.69 0.184 D50 3.55 1.20 D90 7.58 3.57 D4,3 5.94 1.56 D3,2 3.02 0.49 The milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling. The granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 22.
Table 22: Milled Abiraterone Acetate Tablets 125 mg Composition Ingredient % w/w mg/tablet Abiraterone acetate 14.34 125.00 Lactose monohydrate, USP 30.49 265.83 Butylated Hydroxytoluene (BHT) 0.05 0.42 Butylated Hydroxyanisole (BHA) 0.05 0.42 sodium lauryl sulfate, NF 2.87 25.00 Microcrystalline cellulose, NF 44.69 389.63 Croscarmellose sodium ,NF 7.02 61.25 Sodium stearyl fumarate,NF 0.50 4.38 total 100.00 871.92 Tablets were packaged and mounted on accelerated stability at 40 C and 75%
relative humidity.
Impurities were measured by a stability-indicating HPLC method. The dissolution rate of these tablets was measured in at USP Apparatus II, 75rpm in pH 4.5 buffer with 0.12%
SLS. The results are shown in Table 23; no impurity growth was observed over 3 months at 40 C/75%RH, and the dissolution remained unchanged with full dissolution (>85% dissolved) within 10 minutes over 3 months at 40 C/75%RH.
Table 23. Stability of Abiraterone Acetate Tablets, 125mg Abiraterone Acetate Tablets, 125mg 1 month 2 month 3 month Initial 40 C/75%RH 40 C/75%RH 40 C/75%RH
Total Impurities (%AUC) 0.05 <0.05 0.05 <0.05 Avg % Avg % Avg %
Time dissolv Avg % dissolve dissolved (minutes ed %RS dissolve %R d (n=3) %RS (n=3) ) (n=6) D d (n=3) SD D %RSD
4 60.8 10.2 60.3 8.3 63.4 8.0 65.3 8.6 6 81.3 8.3 80.0 5.0 87.2 3.0 85.8 2.9 8 92.1 1.5 91.6 4.2 94.2 1.2 93.8 0.7 93.9 1.2 93.6 2.9 95.5 0.8 95.3 0.6 95.0 1.4 97.4 1.9 97.4 0.6 97.4 0.4 95.3 1.4 97.7 0.6 98.0 0.3 97.3 0.8 95.4 1.9 98.0 0.1 99.3 2.9 97.0 1.2 60 98.1 4.7 97.4 0.7 99.0 1.2 97.2 0.7 Example 14: Effect of Fed or Fasted State The effect of a high fat meal on the oral bioavailability of a 500mg dose of 125mg milled abiraterone mg tablets was evaluated in a single-center, single-dose, randomized, open-label, 2-period, 2-treatment crossover pharmacokinetic study. During the first dosing period, approximately half of the subjects were administered the test article with 240 mL of water, after a 10 hour fast. The remaining subjects were given the test article approximately 30 minutes after consuming a standard FDA high fat breakfast. After a seven day washout period, each subject was crossed over to the other treatment. Plasma samples were taken immediately prior to dosing and at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0, and 48.0 hours after administration of the test article. Samples were analyzed for abiraterone concentration, and the results were used to calculate pharmacokinetic parameters (AUCo-., AUCo-t, and Cmax) for each subject and treatment. The geometric mean values for AUCo-o,, AUCo-t, and Cmax when the test article was administered in the fed state were 1444.1 ng-h/mL, 1393.4 ng-h/mL, and 443.7 ng/mL respectively, while the geometric mean values for those same parameters were 322.7 ng=h/mL, 301.0 ng=h/mL, and 67.9 ng/mL when the drug was administered in the fasted state.
The ratios (fed/fasted) for AUCo-., AUCo-t, and C. were 4.48, 4.63, and 6.53, respectively.
Claims (56)
1. A unit dosage form of abiraterone acetate, wherein a 500mg dose of the unit dosage form is bioequivalent to a 1000mg dose of Zytiga® in healthy male subjects in the fasted state.
2. The unit dosage form of abiraterone acetate of claim 1, wherein the ratio of the log of the geometric mean of the AUC(0-.infin.) for a 500mg dose administered to healthy male subjects in the fasted state compared to a 1000mg dose of Zytiga® administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1.
3. The unit dosage form of abiraterone acetate of claim 1, wherein the ratio of the log of the geometric mean of the C(max) for a 500mg dose administered to healthy male sujects in the fasted state compared to a 1000mg dose of Zytiga® administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1.
4. The unit dosage form of abiraterone acetate of claim 1, wherein the [D90] of the abiraterone acetate is greater than 300nm and less than one of: 7500nm, 7000nm, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm.
5. The unit dosage form of abiraterone acetate of claim 1, wherein the [D50] of the abiraterone acetate greater than 100nm and is less than one of: 3500nm, 3000nm, 2500nm, 1600nm, 1400nm, 1200nm, 1000nm, 800nm, 500nm, 400nm, and 300nm.
6. The unit dosage form of abiraterone acetate of claim 1, wherein the [D4,3] of the abiraterone acetate is greater than 300nm and less than one of: 7000nm, 6000nm, 5000nm, 4000nm, 3000nm, 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 1500nm, 1300nm, 1100nm, 900nm, and 800nm.
7. The unit dosage form of abiraterone acetate of claim 1, whererein the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.1%
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
8. The unit dosage form of abiraterone acetate of claim 1, whererein the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 125mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12%
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
sodium lauryl sulfate using USP Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
9. The unit dosage form of abiraterone acetate of claim 1 containing 125mg of abiraterone acetate.
10. The unit dosage form of abiraterone acetate of claim 1, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma Cmax of 50-120 ng/ml.
11. The unit dosage dosage form of claim 10, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a median blood plasma tmax of 1 to 2.5 hrs.
12. The unit dosage form of abiraterone acetate of claim 1, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma AUC (0-.infin.) of 240-650 h*ng/ml.
13. The unit dosage dosage form of claim 1 containing 125mg of abiraterone acetate.
14. The unit dosage form of abiraterone acetate of claim 1, wherein the 90%
confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
15. The unit dosage form of abiraterone acetate of claim 1, wherein the 90%
confidence interval of the mean blood plasma AUC (0-0o) is a value between 240 and 650 h*ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
confidence interval of the mean blood plasma AUC (0-0o) is a value between 240 and 650 h*ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
16. The unit dosage form of claim 14 containing 125mg of abiraterone acetate.
17. The unit dosage form of any of claim 1 further comprising an antioxidant.
18. A unit dosage form of abiraterone acetate containing 125 mg of abiraterone acetate, wherein the mediam particle size of the abiraterone acetate, on a particle volume basis, is between 2000nm and 100nm.
19. The unit dosage from of claim 18, wherein the dissolution rate of the abiraterone acetate in the unit dosage form is such that when a sample containing 125mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with 0.12% sodium lauryl sulfate using USP
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
Apparatus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
20. The unit dosage form of claim 18, wherein the 90% confidence interval of the mean blood plasma AUC (0-.infin.) is a value between 240 and 650 h*ng/m1 when a 500mg dose is administered to healthy male subjects in the fasted state.
21. The unit dosage forn of claim 18, wherein the 90% confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
22. A method for treating castration resistant prostate cancer comprising administering to a patient in need thereof a daily 500mg dose of a dosage form abiraterone acetate, wherein the 500mg dose is bioequivalent to a 1000mg dose of Zytiga® in healthy male subjects in the fasted state and a glucocorticoid.
23. The method of claim 22 wherein the glucocorticoid is selected from the group consisting of prednisone, prednisolone and methylprednisolone.
24. A method for producing a composition comprising nanoparticles of abiraterone acetate, the method comprising:
dry milling a composition comprising abiraterone acetate, a millable grinding compound, a facilitating agent and one or both of an antioxidant and a sequestering agent in a mill comprising a plurality of milling bodies, for a time period sufficient to produce a composition comprising fine particles of the abiraterone acetate, wherein the the particle size of the abiraterone acetate is reduced by dry milling.
dry milling a composition comprising abiraterone acetate, a millable grinding compound, a facilitating agent and one or both of an antioxidant and a sequestering agent in a mill comprising a plurality of milling bodies, for a time period sufficient to produce a composition comprising fine particles of the abiraterone acetate, wherein the the particle size of the abiraterone acetate is reduced by dry milling.
25. The method of claim 24, wherein [D90] of the abiraterone acetate in the composition comprising fine particles of abiraterone acetate is greater than 100nm and less than one of:
3000nm, 2000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm, and 200nm.
3000nm, 2000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm, and 200nm.
26. The method of claim 24 or claim 25, wherein the milling takes place in the presence of one or both of an antioxidant and a sequestering agent.
27. The method of claim 3, wherein the antioxidant is selected from ascorbic acid, BHA and BHT.
28. The method of claim 26, wherein the sequestering agent is selected from fumaric acid, tartartic acid and citric acid.
29. The method of any of claims 23-28, wherein the [D50] of the fine particles of abiraterone acetate in the composition comprising fine particles of abiraterone acetate greater than 100nm and is less than 2000nm, less than 1600nm, less than 1400nm, less than 1200nm, less than 1000nm, less than 800nm, less than 500nm, less than 400nm, or less than 300nm.
30. The method of any of claims 23-29, wherein the [D4,3] of the fine particles of abiraterone acetate in the composition comprising fine particles of abiraterone acetate is greater than 100nm and less than one of: 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 1500nm, 1300nm, 1100nm, 1000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400nm, and 300nm.
31. A method for preparing a unit dosage composition comprising: preparing a composition comprising fine particles of abiraterone acetate according to the method of any of the forgoing claims, combining the composition comprising fine particles of abiraterone acetate with one or more pharmaceutically acceptable diluents, disintegrants, lubricants, glidants or dispersants.
32. The method of claim 31, wherein the unit dosage compositon is a tablet or capsule.
33. The method of claim 32, wherein the unit dosage composition contains 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375 or 400mg of abiraterone acetate.
34. The method of claim 33, whererein the dissolution rate of the abiraterone acetate in the unit dosage composition is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer (0.1% SLS) using USP Apptartus II
at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or in between 5 and 10 min.
at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or in between 5 and 10 min.
35. The method of claim 33 or 34, wherein the unit dosage composition is a tablet and the dissolution rate is such that when the tablet is tested in 900 ml of pH 4.5 phosphate buffer (0.1%
SLS) using USP Apptartus II at 75 rpm, at least 80% of the abiraterone acetate dissolves in between 5 and 15 min or in between 5 and 10 min.
SLS) using USP Apptartus II at 75 rpm, at least 80% of the abiraterone acetate dissolves in between 5 and 15 min or in between 5 and 10 min.
36. A unit dosage pharmaceutical composition comprising abiraterone acetate, wherin the [D90] of the abiraterone acetate in the composition is greater than 100nm and less than one of:
5,000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm, and 200nm.
5,000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm, and 200nm.
37. The unit dosage pharmaceutical composition of claim 36, wherein the [D50] of the abiraterone acetate greater than 100nm and is less than 2000nm, less than 1600nm, less than 1400nm, less than 1200nm, less than 1000nm, less than 800nm, less than 500nm, less than 400nm, less than 300nm.
38. The unit dosage pharmaceutical composition of claim 36 or claim 37, wherein the [D4,3]
of the abiraterone acetate is greater than 100nm and less than one of: 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 600nm, 500nm, 400 nm, and 300nm.
of the abiraterone acetate is greater than 100nm and less than one of: 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 600nm, 500nm, 400 nm, and 300nm.
39. The unit dosage composition of any of claims 36-38, whererein the dissolution rate of the abiraterone acetate in the unit dosage composition is such that when a sample containing 100mg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer (0.1%
SLS) using USP
Apptartus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
SLS) using USP
Apptartus II at 75 rpm, at least 70% of the abiraterone acetate dissolves in between 5 and 15 min or between 5 and 10 min.
40. The unit dosage composition of any of claims 36-39, wherein wherein the mean AUC 0-.infin.
of the unit dosage composition when administered to an adult male with a low-fat meal (7% fat, 300 calories) is 2-fold or less higher than when administered in the fasted state.
of the unit dosage composition when administered to an adult male with a low-fat meal (7% fat, 300 calories) is 2-fold or less higher than when administered in the fasted state.
41. The unit dosage composition of any of claims 36-40, wherein the mean AUC 0-.infin. of the unit dosage composition when administered to an adult male with a high-fat meal (57% fat, 825 calories) is 2-fold or less higher than when administered in the fasted state.
42. The unit dosage composition of any of claims 36-41, wherein the mean Cmax of the unit dosage composition when administered to an adult male with a low-fat meal (7%
fat, 300 calories) is 2-fold or less higher than when administered in the fasted state.
fat, 300 calories) is 2-fold or less higher than when administered in the fasted state.
43. The unit dosage compostion of any of claims 36-42, wherein the mean Cmax of the unit dosage compositin when administered to an adult male with a high-fat meal (57%
fat, 825 calories) is 5-fold or less higher than when administered in the fasted state.
fat, 825 calories) is 5-fold or less higher than when administered in the fasted state.
44. The unit dosage compostion of any of claims 36-42 wherein a 500mg dose of the unit dosage composition is bioequivalent to a 1,000mg dose of Zytiga with respect to one or both of Cmax and AUC0-t in healthy male patients when administered in the fasted state.
45. The unit dosage compostion of any of claims 36-44 wherein a 500mg dose of the unit dosage composition is bioequivalent to a 1,000mg dose of Zytiga with respect to both Cmax and AUC0-t in healthy male patients when administered in the fasted state.
46. The unit dosage composition of any of claims 36-45 wherein the unit dose composition contains 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375 or 400mg of abiraterone acetate.
47. A method of treating castration resistant prostate cancer comprising administering a daily dose of 100-700 mg of abiraterone acetate wherein the abiraterone acetate has a [D4,3] of greater than 100nm and less than one of: 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 600nm, 500nm, 400 nm, and 300nm.
48. The method of claim 47 comprising administering 200-600 mg of abiraterone acetate.
49. The method of claim 48 comprising administering 300-600 mg of abiraterone acetate.
50. A method of treating castration resistant prostate cancer comprising administering a daily dose of 100-700 mg of abiraterone acetate in the form of a unit dosage form of any of claims 36-47.
51. The method claim 50 wherein the daily dose is 500 mg of abiraterone acetate.
52. The method of any of claims 48-51 further comprising administering a glucocorticoid.
53. The method of claim 52 wherein the glucorticoid is prednisone.
54. The method of claim 52 wherein the glucorticoid is prednisolone.
55. The method of claim 52 wherein the glucorticoid in methylprednisolone.
56. A pharmaceutical composition prepared by a method comprising the method of any of claims 23-34.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462052294P | 2014-09-18 | 2014-09-18 | |
US62/052,294 | 2014-09-18 | ||
US14/707,922 US20150246060A1 (en) | 2013-03-15 | 2015-05-08 | Abiraterone Acetate Formulation and Methods of Use |
US14/707,922 | 2015-05-08 | ||
PCT/US2015/050889 WO2016044701A1 (en) | 2014-09-18 | 2015-09-18 | Abiraterone acetate formulation and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2958316A1 true CA2958316A1 (en) | 2016-03-24 |
Family
ID=55533897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2958316A Pending CA2958316A1 (en) | 2014-09-18 | 2015-09-18 | Abiraterone acetate formulation and methods of use |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP3193857A4 (en) |
JP (1) | JP2017528457A (en) |
KR (2) | KR102491439B1 (en) |
CN (1) | CN106687112A (en) |
AP (1) | AP2017009804A0 (en) |
AU (1) | AU2015317466A1 (en) |
BR (1) | BR112017003219A2 (en) |
CA (1) | CA2958316A1 (en) |
CO (1) | CO2017002472A2 (en) |
EA (1) | EA201790650A1 (en) |
IL (1) | IL250270B (en) |
MD (1) | MD20170048A2 (en) |
MX (1) | MX2017003525A (en) |
PH (1) | PH12017500239A1 (en) |
SG (1) | SG11201701139YA (en) |
TN (2) | TN2017000098A1 (en) |
WO (1) | WO2016044701A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
KR20200021451A (en) * | 2017-04-07 | 2020-02-28 | 엠에이에이 래보러토리스, 인코포레이티드 | How to improve the solubility and bioavailability of therapeutic agents |
EP3914234A4 (en) * | 2019-01-25 | 2022-09-14 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
WO2020180942A1 (en) | 2019-03-06 | 2020-09-10 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
CN110742870B (en) * | 2019-12-04 | 2021-04-20 | 武汉大学 | Abiraterone acetate preparation and preparation method thereof |
CN111110646A (en) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | Prescription and preparation method of low-specification abiraterone acetate oral preparation |
CN113384542B (en) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof |
BR112022021732A2 (en) * | 2020-05-08 | 2022-12-06 | Janssen Pharmaceutica Nv | PROSTATE CANCER TREATMENTS WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB |
EP3944860A1 (en) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
CA3207282A1 (en) | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
KR20240044329A (en) | 2022-09-28 | 2024-04-04 | 한미약품 주식회사 | Oral composite tablet comprising abiraterone acetate and prednisolone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX359793B (en) * | 2009-04-24 | 2018-10-08 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale. |
GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
CN102743393A (en) | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | Medicinal composition containing abiraterone acetate and preparation technology thereof |
NZ712350A (en) * | 2013-03-15 | 2020-08-28 | Sun Pharma Global Fze | Abiraterone acetate formulation |
-
2015
- 2015-09-18 CA CA2958316A patent/CA2958316A1/en active Pending
- 2015-09-18 MX MX2017003525A patent/MX2017003525A/en unknown
- 2015-09-18 WO PCT/US2015/050889 patent/WO2016044701A1/en active Application Filing
- 2015-09-18 EP EP15842591.8A patent/EP3193857A4/en not_active Withdrawn
- 2015-09-18 EA EA201790650A patent/EA201790650A1/en unknown
- 2015-09-18 JP JP2017512783A patent/JP2017528457A/en active Pending
- 2015-09-18 KR KR1020177008938A patent/KR102491439B1/en active IP Right Grant
- 2015-09-18 KR KR1020237001893A patent/KR102617537B1/en active IP Right Grant
- 2015-09-18 AP AP2017009804A patent/AP2017009804A0/en unknown
- 2015-09-18 TN TN2017000098A patent/TN2017000098A1/en unknown
- 2015-09-18 TN TNP/2018/000318A patent/TN2018000318A1/en unknown
- 2015-09-18 SG SG11201701139YA patent/SG11201701139YA/en unknown
- 2015-09-18 AU AU2015317466A patent/AU2015317466A1/en not_active Abandoned
- 2015-09-18 CN CN201580050453.8A patent/CN106687112A/en active Pending
- 2015-09-18 BR BR112017003219A patent/BR112017003219A2/en not_active IP Right Cessation
- 2015-09-18 MD MDA20170048A patent/MD20170048A2/en not_active Application Discontinuation
-
2017
- 2017-01-25 IL IL250270A patent/IL250270B/en active IP Right Grant
- 2017-02-09 PH PH12017500239A patent/PH12017500239A1/en unknown
- 2017-03-15 CO CONC2017/0002472A patent/CO2017002472A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102491439B1 (en) | 2023-01-25 |
IL250270B (en) | 2021-02-28 |
EP3193857A1 (en) | 2017-07-26 |
BR112017003219A2 (en) | 2017-11-28 |
PH12017500239A1 (en) | 2017-07-03 |
TN2018000318A1 (en) | 2020-01-16 |
CN106687112A (en) | 2017-05-17 |
KR20230014878A (en) | 2023-01-30 |
WO2016044701A1 (en) | 2016-03-24 |
AP2017009804A0 (en) | 2017-03-31 |
EA201790650A1 (en) | 2017-07-31 |
MX2017003525A (en) | 2017-06-21 |
TN2017000098A1 (en) | 2018-10-19 |
CO2017002472A2 (en) | 2017-07-11 |
JP2017528457A (en) | 2017-09-28 |
KR102617537B1 (en) | 2023-12-22 |
EP3193857A4 (en) | 2018-04-11 |
IL250270A0 (en) | 2017-03-30 |
AU2015317466A1 (en) | 2017-02-23 |
SG11201701139YA (en) | 2017-03-30 |
KR20170070025A (en) | 2017-06-21 |
MD20170048A2 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018241103B2 (en) | Abiraterone Acetate Formulation | |
US9889144B2 (en) | Abiraterone acetate formulation and methods of use | |
KR102617537B1 (en) | Abiraterone acetate formulation and methods of use | |
US10292990B2 (en) | Abiraterone steroid formulation | |
US20210101873A1 (en) | Formulation of metaxalone | |
OA18485A (en) | Abiraterone acetate formulation and methods of use. | |
OA18169A (en) | Abiraterone acetate formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |
|
EEER | Examination request |
Effective date: 20200827 |